Update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 9: suitability of taxonomic units notified to EFSA until September 2018

Abstract

The qualified presumption of safety (QPS) procedure was developed to provide a harmonised generic pre-evaluation to support safety risk assessments of biological agents performed by EFSA’s Scientific Panels. The taxonomic identity, body of knowledge, safety concerns and antimicrobial resistance were assessed. Safety concerns identified for a taxonomic unit are, where possible and reasonable in number, reflected by ‘qualifications’ which should be assessed at the strain level by the EFSA’s Scientific Panels. During the current assessment, no new information was found that would change the previously recommended QPS taxonomic units and their qualifications. Between April and September 2018, the QPS notification list was updated with 48 microorganisms from applications for market authorisation. Of these, 30 biological agents already had QPS status, 15 were excluded from the QPS exercise by the previous QPS mandate (five filamentous fungi) or from further evaluations within the current mandate (two notifications of Enterococcus faecium, one of Streptomyces spp. and seven of Escherichia coli). One taxonomic unit was (re)evaluated: Pseudomonas fluorescens had been previously evaluated in 2016, and was now re-evaluated within this mandate. The revision of the literature supports the previously identified safety concerns (e.g. production of biocompounds with antimicrobial activity and virulence features), preventing the inclusion of P. fluorescens in the QPS list. Mycobacterium setense and Komagataeibacter sucrofermentans were evaluated for the first time. M. setense cannot be considered for the QPS assessment because there are significant safety concerns. K. sucrofermentans (Acetobacter xylinus subsp. sucrofermentans) can be proposed for the QPS list but only for production purposes. The QPS status of Corynebacterium glutamicum is confirmed with the qualification extended to other production purposes.

Keywords: safety, QPS, bacteria, yeast, Pseudomonas fluorescens, Mycobacterium setense, Komagataeibacter sucrofermentans, Corynebacterium glutamicum

Requestor: EFSA

Question number: EFSA-Q-2016-00830

Correspondence: biohaz@efsa.europa.eu
Panel members: Ana Allende, Avelino Álvarez-Ordóñez, Declan Bolton, Sara Bover-Cid, Marianne Chemaly, Robert Davies, Alessandra De Cesare, Lieve Herman, Friederike Hilbert, Kostas Koutsoumanis, Roland Lindqvist, Maarten Nauta, Luisa Peixe, Giuseppe Ru, Marion Simmons, Panagiotis Skandamis and Elisabetta Suffredini.

Acknowledgements: The Panel wishes to thank EFSA staff members Jaime Aguilera, Rosella Brozzi, Leng Heng and Frédérique Istace for the support provided to this Statement.

Suggested citation: EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards), Koutsoumanis K, Allende A, Alvarez-Ordóñez A, Bolton D, Bover-Cid S, Chemaly M, Davies R, Hilbert F, Lindqvist R, Nauta M, Peixe L, Ru G, Simmons M, Skandamis P, Suffredini E, Cocconcelli PS, Fernández Escámez PS, Maradona MP, Querol A, Suarez JE, Sundh I, Vlak J, Barizzone F, Correia S and Herman L, 2019. Statement on the update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 9: suitability of taxonomic units notified until September 2019. EFSA Journal 2019;17(1):5555, 46 pp. https://doi.org/10.2903/j.efsa.2019.5555

ISSN: 1831-4732

© 2019 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.
Summary

The European Food Safety Authority (EFSA) asked the Panel on Biological Hazards (BIOHAZ) to deliver a Scientific Opinion on the maintenance of the list of qualified presumption of safety (QPS) biological agents intentionally added to food or feed. The request included three specific tasks as mentioned in the Terms of Reference (ToR).

The QPS process was developed to provide a harmonised generic pre-evaluation procedure to support safety risk assessments of biological agents performed by EFSA's scientific Panels and Units. The taxonomic identity, body of knowledge and safety of biological agents are assessed. Safety concerns identified for a taxonomic unit (TU) are, where possible and reasonable in number, reflected as ‘qualifications’ that should be assessed at the strain level by the EFSA's scientific Panels. A generic qualification for all QPS bacterial TUs applies in relation to the absence of acquired genes conferring resistance to clinically relevant antimicrobials (EFSA, 2008).3

The evaluation is undertaken every 3 years in a scientific Opinion of the BIOHAZ Panel. Meanwhile, the list of microorganisms is maintained and re-evaluated approximately every 6 months in a Panel Statement. If new information is retrieved from extended literature searches that would change the QPS status of a microbial species or its qualifications, this is published in the Panel Statement. The Panel Statement also includes the evaluation of microbiological agents notified to EFSA within the 6-month period for an assessment for use as feed additives, food enzymes, food additives and flavourings, novel foods or plant protection products (PPP). The main results of the assessments completed from 2017 will be included in the scientific Opinion of the BIOHAZ Panel to be published by the end of the current mandate in December 2019. In the interim, as a result of each Panel Statement, the '2016 updated list of QPS status recommended biological agents for safety risk assessments carried out by EFSA scientific Panels and Units’ is extended by the inclusion of new recommendations for QPS status, and appended to the Opinion adopted in December 2016 (Appendix E).

The first ToR requires ongoing updates of the list of biological agents notified to EFSA, in the context of a technical dossier, for intentional use in food and/or feed or as sources of food and feed additives, enzymes and PPP for safety assessment. The list was updated with the notifications received since the latest review in March 2018. Within this period, 48 notifications were received by EFSA, of which 41 were for feed additives, three for food enzymes, food additives and flavourings, four for novel foods and none for PPP. The new notifications, received between April and September 2018, are included in a table appended to the current Statement (Appendix F).

The second ToR concerns the revision of the TUs previously recommended for the QPS list and their qualifications when new information has become available, and the updating of the information provided in the previous Opinion adopted in December 2016. According to the articles retrieved through an extensive literature search (ELS), for articles published from January to June 2018 no new information was found that would affect the QPS status of those TUs and their qualifications.

The third ToR requires a (re)assessment of TUs notified to EFSA, but not present in the current QPS list, for their suitability for inclusion in the updated list. The current Statement focuses on the assessments of the TUs that were notified to EFSA between April 2018 and September 2018. Of the 48 notifications received, 30 biological agents already had QPS status and did not require further evaluation in this Statement and 15 were not included because: five were notifications of filamentous fungi that were excluded from the QPS exercise; two were notifications of Enterococcus faecium, one of Streptomyces spp. and seven of Escherichia coli that were excluded from further QPS evaluations within the current QPS mandate. Three new TUs were considered for the QPS assessment within this Statement: Pseudomonas fluorescens, already evaluated in 2016 (EFSA BIOHAZ Panel, 2017a), and was re-evaluated within this mandate and Mycobacterium setense and Komagataeibacter sucrofermentans, which were evaluated for the first time.

The revision of the literature supports the previous identified safety concerns (e.g. production of biocompounds with antimicrobial activity and virulence features), preventing the inclusion of P. fluorescens in the QPS list. M. setense cannot be considered for the QPS assessment because there are significant safety concerns. K. sucrofermentans (Acetobacter xylinus subsp. sucrofermentans) can be proposed for the QPS list but only for production purposes.

In parallel to the standard procedure for assessing a TU for a possible QPS status, in relation to Corynebacterium glutamicum, and in response to a request from an EFSA unit, it was decided to run a complementary reassessment for another specific end-use as the QPS qualification ‘only applies when the species is used for amino acid production’. The QPS status of C. glutamicum is confirmed with the qualification extended to other production purposes.
Table of contents

Abstract ............................................................................................................................................. 1
Summary ........................................................................................................................................... 3
1. Introduction .................................................................................................................................... 6
1.1. Background and Terms of Reference as provided by EFSA ....................................................... 6
1.1.1. Background as provided by EFSA ............................................................................................. 6
1.1.2. Terms of Reference as provided by EFSA ............................................................................... 7
1.2. Interpretation of the Terms of Reference .................................................................................. 7
2. Data and methodologies ............................................................................................................... 8
2.1. Data ........................................................................................................................................... 8
2.2. Methodologies ........................................................................................................................... 8
2.2.1. Evaluation of a QPS recommendation for Taxonomic Units notified to EFSA ......................... 8
2.2.2. Monitoring of new safety concerns related to the QPS list ...................................................... 9
3. Assessment ................................................................................................................................... 10
3.1. Taxonomic Units evaluated during the previous QPS mandate and re-evaluated in the current Statement... 10
3.1.1. Pseudomonas fluorescens ......................................................................................................... 10
3.1.1.1. Identity .................................................................................................................................. 10
3.1.1.1.2. Body of knowledge ............................................................................................................. 10
3.1.1.1.3. Safety concerns .................................................................................................................... 11
3.1.1.1.4. Antimicrobial resistance aspects ......................................................................................... 11
3.1.1.1.5. Conclusions on a recommendation for the QPS list ........................................................ 11
3.2. Taxonomic Units to be evaluated for the QPS .......................................................................... 11
3.2.1. Mycobacterium setense .......................................................................................................... 11
3.2.1.1. Identity .................................................................................................................................. 11
3.2.1.1.2. Body of knowledge ............................................................................................................. 11
3.2.1.1.3. Safety concerns .................................................................................................................... 11
3.2.1.1.4. Antimicrobial resistance aspects ......................................................................................... 11
3.2.1.1.5. Conclusions on a recommendation for the QPS list ........................................................ 11
3.2.2. Komagataeibacter sucrofermentans ....................................................................................... 11
3.2.2.1. Identity .................................................................................................................................. 11
3.2.2.1.2. Body of knowledge ............................................................................................................. 11
3.2.2.1.3. Safety concerns .................................................................................................................... 11
3.2.2.1.4. Antimicrobial resistance aspects ......................................................................................... 11
3.2.2.1.5. Conclusions on a recommendation for the QPS list ........................................................ 11
3.2.3. Extension of qualification of Corynebacterium glutamicum ..................................................... 12
3.2.3.1. Lactobacillus spp. ................................................................................................................... 12
3.2.3.1.1. Identity .................................................................................................................................. 12
3.2.3.1.1.2. Body of knowledge ............................................................................................................. 12
3.2.3.1.1.3. Safety concerns .................................................................................................................... 12
3.2.3.1.1.4. Antimicrobial resistance aspects ......................................................................................... 12
3.2.3.1.1.5. Conclusions on a recommendation for the QPS list ........................................................ 12
3.2.4. Gram-positive non-sporulating bacteria ................................................................................ 12
3.2.4.1. Bifidobacterium spp. .............................................................................................................. 12
3.2.4.1.1. Identity .................................................................................................................................. 12
3.2.4.1.1.2. Body of knowledge ............................................................................................................. 12
3.2.4.1.1.3. Safety concerns .................................................................................................................... 12
3.2.4.1.1.4. Antimicrobial resistance aspects ......................................................................................... 12
3.2.4.1.1.5. Conclusions on a recommendation for the QPS list ........................................................ 12
3.2.5. Monitoring of new safety concerns related to organisms on the QPS list .............................. 12
3.2.5.1. Carnobacterium divergens ..................................................................................................... 12
3.2.5.1.1. Identity .................................................................................................................................. 12
3.2.5.1.1.2. Body of knowledge ............................................................................................................. 12
3.2.5.1.1.3. Safety concerns .................................................................................................................... 12
3.2.5.1.1.4. Antimicrobial resistance aspects ......................................................................................... 12
3.2.5.1.1.5. Conclusions on a recommendation for the QPS list ........................................................ 12
3.2.6. Gram-positive spore-forming bacteria ................................................................................... 14
3.2.6.1. Leuconostoc spp. .................................................................................................................... 14
3.2.6.1.1. Identity .................................................................................................................................. 14
3.2.6.1.1.2. Body of knowledge ............................................................................................................. 14
3.2.6.1.1.3. Safety concerns .................................................................................................................... 14
3.2.6.1.1.4. Antimicrobial resistance aspects ......................................................................................... 14
3.2.6.1.1.5. Conclusions on a recommendation for the QPS list ........................................................ 14
3.2.7. Microbacterium imperiale ....................................................................................................... 14
3.2.7.1. Oenococcus oeni ...................................................................................................................... 14
3.2.7.1.1. Identity .................................................................................................................................. 14
3.2.7.1.1.2. Body of knowledge ............................................................................................................. 14
3.2.7.1.1.3. Safety concerns .................................................................................................................... 14
3.2.7.1.1.4. Antimicrobial resistance aspects ......................................................................................... 14
3.2.7.1.1.5. Conclusions on a recommendation for the QPS list ........................................................ 14
3.2.8. Pasteuria nishizawai ................................................................................................................ 14
3.2.8.1. Pediococcus spp. ...................................................................................................................... 14
3.2.8.1.1. Identity .................................................................................................................................. 14
3.2.8.1.1.2. Body of knowledge ............................................................................................................. 14
3.2.8.1.1.3. Safety concerns .................................................................................................................... 14
3.2.8.1.1.4. Antimicrobial resistance aspects ......................................................................................... 14
3.2.8.1.1.5. Conclusions on a recommendation for the QPS list ........................................................ 14
3.2.9. Streptococcus thermophilus ...................................................................................................... 14
3.2.9.1. Bacillus spp. ............................................................................................................................ 14
3.2.9.1.1. Identity .................................................................................................................................. 14
3.2.9.1.1.2. Body of knowledge ............................................................................................................. 14
3.2.9.1.1.3. Safety concerns .................................................................................................................... 14
3.2.9.1.1.4. Antimicrobial resistance aspects ......................................................................................... 14
3.2.10. Gram-negative bacteria ......................................................................................................... 15
3.2.10.1. Geobacillus stearothermophilus ......................................................................................... 15
3.2.10.1.1. Identity .................................................................................................................................. 15
3.2.10.1.1.2. Body of knowledge ............................................................................................................. 15
3.2.10.1.1.3. Safety concerns .................................................................................................................... 15
3.2.10.1.1.4. Antimicrobial resistance aspects ......................................................................................... 15
3.2.10.1.1.5. Conclusions on a recommendation for the QPS list ........................................................ 15
3.2.11. Xanthomonas campestris ....................................................................................................... 15
3.2.12. Yeasts ..................................................................................................................................... 16
3.2.12.1. Alphaflexiviridae .................................................................................................................. 16
3.2.12.1.1. Alphaflexiviridae .................................................................................................................... 16
3.2.12.2. Baculoviridae ......................................................................................................................... 16
4. Conclusions ..................................................................................................................................... 16
1. Introduction

The qualified presumption of safety (QPS) approach was developed by the EFSA Scientific Committee to provide a generic concept to prioritise and to harmonise risk assessment within the European Food Safety Authority (EFSA) of microorganisms intentionally introduced into the food chain, in support of the respective Scientific Panels and Units in the frame of market authorisations (EFSA, 2007a). The list, first established in 2007, has been continuously revised and updated. The publication of the overall assessment of the taxonomic units (TUs) previously recommended for the QPS list is to be evaluated every 3 years through a scientific Opinion by the Panel on Biological Hazards (BIOHAZ). Intermediate deliverables in the form of a Panel Statement are produced and published for periods of around 6 months, should an assessment for a QPS classification of a microbiological agent notified to EFSA be requested by the Units dealing with feed additives, food enzymes, food additives and flavourings, novel foods, or plant protection products. These Panel Statements also include the results of the assessment of the relevant new papers related to the TUs with QPS status.

1.1. Background and Terms of Reference as provided by EFSA

1.1.1. Background as provided by EFSA

A wide variety of microorganisms are intentionally added at different stages into the food and feed chain. In the context of applications for market authorisation of these biological agents, used either directly or as sources of food and feed additives, food enzymes and plant protection products, EFSA is requested to assess their safety.

Several taxonomic units (usually species for bacteria and yeasts, families for viruses) have been included in the qualified presumption of safety (QPS) list either following notifications to EFSA or proposals made initially by stakeholders during a public consultation in 2005, even if they were not yet notified to EFSA (EFSA, 2005). The EFSA Scientific Committee reviewed the range and numbers of microorganisms likely to be the subject of an EFSA Opinion and published in 2007 a list of microorganisms recommended for the QPS list.

In 2007, the Scientific Committee recommended that a QPS approach should provide a generic concept to prioritise and to harmonise risk assessment of microorganisms intentionally introduced into the food chain, in support of the respective Scientific Panels and EFSA Units in the frame of the market authorisations. The same Committee recognised that there would have to be continuing provision for reviewing and modifying the QPS list and in line with this recommendation, the EFSA Scientific Panel on Biological Hazards (BIOHAZ) took the prime responsibility for this and started reviewing annually the existing QPS list. The first annual QPS update was published in 2008 and EFSA's initial experience in applying the QPS approach was included. The potential application of the QPS approach to microbial plant protection products was discussed in the 2009 update. Also in 2009, bacteriophages were assessed and were not considered appropriate for the QPS list. After consecutive years of reviewing the existing scientific information, the filamentous fungi (2008 to 2013 updates) and enterococci (2010 to 2013 updates) were not recommended for the QPS list. The 2013 update of the recommended QPS list included 53 species of Gram-positive non-spore-forming bacteria, 13 Gram-positive spore forming bacteria (Bacillus species), one Gram-negative bacterium (Gluconobacter oxydans), 13 yeast species, and three virus families.

In 2014 the BIOHAZ Panel, in consultation with the Scientific Committee, decided to change the revision procedure: the overall assessment of the taxonomic units previously recommended for the QPS list is no longer carried out annually but over 3-year periods. From 2017, the search and revision of the possible safety concerns linked to those taxonomic units start to be done every 6 months.

1 Opinion of the Scientific Committee on a request from EFSA related to a generic approach to the safety assessment by EFSA of microorganisms used in food/feed and the production of food/feed additives. EFSA Journal 2005;2:226, 1–12.
2 Introduction of a Qualified Presumption of Safety (QPS) approach for assessment of selected microorganisms referred to EFSA - Opinion of the Scientific Committee. EFSA Journal 2007;293, 1–85.
3 Scientific Opinion of the Panel on Biological Hazards on a request from EFSA on the maintenance of the list of QPS microorganisms intentionally added to food or feed. EFSA Journal 2008;923, 1–48.
4 Scientific Opinion of the Panel on Biological Hazards (BIOHAZ) on the maintenance of the list of QPS microorganisms intentionally added to food or feed (2009 update). EFSA Journal 2009;7(12):1431, 92 pp. https://doi.org/10.2903/j.efsa.2009.1431
5 EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards), 2013. Scientific Opinion on the maintenance of the list of QPS microorganisms intentionally added to food and feed (2013 update). EFSA Journal 2013;11(11):3449, 107 pp. https://doi.org/10.2903/j.efsa.2013.3449
period. The update of the 2013 QPS list version (EFSA BIOHAZ Panel, 2013) was done in 2016 (EFSA BIOHAZ Panel, 2017a) and the next update will be published in a scientific Opinion of the BIOHAZ Panel after its adoption in December 2019.6 The QPS list of microorganisms has been maintained and frequently checked, based on the evaluation of extensive literature searches. In the meantime and every 6 months, a Panel Statement, compiling the assessments for a QPS status of the microbiological agents notified to EFSA requested by the Feed Unit, the Food Ingredients and Packaging (FIP) Unit, the Nutrition Unit or by the Pesticides Unit, has been produced and published. In the follow up of the 2013 update5 the Scientific Committee agreed to exclude some biological groups (filamentous fungi, bacteriophages and Enterococcus faecium7) notified to EFSA from the QPS assessment because it was considered unlikely that any taxonomical units within these groups would be granted QPS status in the foreseeable future. Thus, the assessment of members of these biological groups needs to be done at a strain level, on a case-by-case basis, by the relevant EFSA Unit.

The QPS provides a generic safety pre-assessment approach for use within EFSA that covers risks for human, animals and the environment. In the QPS concept a safety assessment of a defined taxonomic unit is considered independently of any particular specific notification in the course of an authorisation process. The QPS concept does not address hazards linked to the formulation or other processing of the products containing the microbial agents and added into the food or feed chain. Although general human safety is part of the evaluation, specific issues connected to type and level of exposure of users handling the product (e.g. dermal, inhalation, ingestion) are not addressed. In the case Genetically Modified Microorganisms (GMM) for which the species of the recipient strain qualifies for the QPS status, and for which the genetically modified state does not give rise to safety concerns, the QPS approach can be extended to genetically modified production strains (EFSA BIOHAZ Panel, 2018a).8 Assessment of potential allergenicity to microbial residual components is beyond the QPS remit; if there is however, science-based evidence for some microbial species it is reported. Where applicable these aspects are assessed, separately by the EFSA Panel responsible for assessing the notification. Antimicrobial resistance was introduced as a possible safety concern for the assessment of the inclusion of bacterial species in the QPS list published in 2008 QPS Opinion (EFSA, 2008)3. In the 2009 QPS Opinion (EFSA BIOHAZ Panel, 2009)9 a qualification regarding the absence of antimycotic resistance for yeasts was introduced.

1.1.2. Terms of Reference as provided by EFSA

The Terms of Reference, as provided by EFSA are as follows:

ToR 1: Keep updated the list of biological agents being notified in the context of a technical dossier to EFSA Units such as Feed, Pesticides, Food Ingredients and Packaging (FIP) and Nutrition, for intentional use directly or as sources of food and feed additives, food enzymes and plant protection products for safety assessment.

ToR 2: Review taxonomic units previously recommended for the QPS list and their qualifications when new information has become available. The latter is based on a review of the updated literature aiming at verifying if any new safety concern has arisen that could require the removal of the taxonomic unit from the list, and to verify if the qualifications still efficiently exclude safety concerns.

ToR 3: (Re) assess the suitability of new taxonomic units notified to EFSA for their inclusion in the QPS list. These microbiological agents are notified to EFSA and requested by the Feed Unit, the FIP Unit, the Nutrition Unit or by the Pesticides Unit.

1.2. Interpretation of the Terms of Reference

The absence of acquired genes conferring resistance to clinically relevant antimicrobials is a qualification9 applied to all QPS bacterial TUs. The verification of such qualification is under the remit of the Unit conducting the safety assessment of the organism notified to EFSA for market authorisation, therefore is done at strain level (EFSA BIOHAZ Panel, 2017a).

6 References updated from the original self-task mandate.
7 The taxonomic unit was corrected from the original mandate: ‘enterococci’. It is only referred to Enterococcus faecium, the only species which was evaluated for a possible QSP status.
8 Sentence included, correcting the previous sentence from the original self-task mandate: ‘Genetically modified microorganisms are similarly not taken into account’.
9 Identifiable safety concerns, including acquired antimicrobial resistance genes, for a certain TU can be, where reasonable in number and not universally present, reflected as ‘qualifications’.
In June of 2017 (EFSA BIOHAZ Panel, 2017b), the BIOHAZ Panel has agreed to exclude *Escherichia coli* and any species of the genus *Streptomyces* from QPS evaluation within this mandate. In June of 2018 (EFSA BIOHAZ Panel, 2018b), the BIOHAZ Panel clarified that the qualification ‘for production purpose only’ implies the absence of viable cells of the production organism in the final product and can also be applied for food and feed products based on microbial biomass.

**2. Data and methodologies**

**2.1. Data**

Only valid TUs covered by the relevant international committees on the nomenclature for microorganisms are considered for the QPS assessment.

In reply to ToR 3, (re)assessment of the suitability of TUs notified within the time period covered by this Statement (from April to September 2018) is carried out. The literature review considered the identification, the body of knowledge, the potential safety concerns, and the knowledge on acquired antimicrobial resistance (AMR). Relevant databases, such as PubMed, Web of Science, Cases Database, CAB Abstracts or Food Science Technology Abstracts (FSTA) and Scopus, were searched. More details on the search strategy, search keys, and approach are described in Appendix A.

In reply to ToR 2, concerning the revision of the TUs previously recommended for the QPS list and their qualifications, an extensive literature search (ELS) was conducted as described in Appendices B and C.

**2.2. Methodologies**

**2.2.1. Evaluation of a QPS recommendation for Taxonomic Units notified to EFSA**

In response to ToR 1, the EFSA Units were asked to update the list of biological agents being notified to EFSA. A total of 48 notifications were received between April and September 2018, of which 41 were for a feed additive, three for food enzymes, food additives and flavourings, four for novel foods and none for plant protection products (Table 1).

In response to ToR 3, out of the 48 notifications, 30 were related to TUs that already had QPS status and did not require further evaluation. Of the remaining 18 notifications, 15 were related to TUs not evaluated for a QPS status for the following reasons:

- Five notifications related to filamentous fungi, which were excluded from QPS evaluations in the follow up of a recommendation of the QPS 2013 and 2016 updates (EFSA BIOHAZ Panel, 2013, 2014, 2016),
- Seven notification related to *E. coli*, one to *Streptomyces* spp. and two of *Enterococcus faecium*, which were recently excluded from the current mandate by the BIOHAZ Panel.

The TUs corresponding to the remaining three notifications were now evaluated (or re-evaluated if they had been evaluated prior to 2016) for possible QPS recommendation:

- *Pseudomonas fluorescens* already evaluated in 2016 and not granted QPS status (EFSA BIOHAZ Panel, 2017a),
- *Mycobacterium setense* and *Komagataeibacter sucrofermentans*, both evaluated for the first time.

In parallel to the standard procedure for assessing a TU for a possible QPS status, and in response to a request from an EFSA unit, in relation to *Corynebacterium glutamicum*, it was decided to run a complementary reassessment for another specific end-use as the QPS qualification ‘only applies when the species is used for amino acid production’, considering that some time passed by since 2016 and that new data may have been published.

The notifications received by EFSA, per risk assessment area, by biological group from April to September 2018 are presented in Table 1.
2.2.2. Monitoring of new safety concerns related to the QPS list

The aim of the ELS carried out in response to ToR 2 (review of the recommendations for the QPS list and specific qualifications) was to identify any publicly available studies reporting on safety concerns for humans, animals or the environment caused by QPS organisms since the previous QPS review (i.e. publications from January to June 2018). For a detailed protocol of the process and search strategies, refer to Appendices B and C.

After removal of duplicates, 3,034 records were submitted to the title screening step, which led to the exclusion of 2,918 of them. The remaining 116 records were found eligible for the title/abstract screening step, which led to the exclusion of 58 of these. Of the 58 articles that finally reached the Article evaluation step (full text), 35 were considered to be relevant for the QPS project.

The flow of records from their identification by the different search strategies (as reported in Appendix C) to their consideration potentially relevant papers for QPS, is shown in Table 2.

Table 1: Notifications received by EFSA, per risk assessment area and by biological group, from April to September 2018

| Risk assessment area | Not evaluated in this statement | Evaluated in this statement | Total |
|----------------------|--------------------------------|-----------------------------|-------|
| Feed additives       |                                |                             |       |
| Bacteria             | 28                             | 12                          | 31    |
| Filamentous fungi    | 0                              | 4                           | 4     |
| Yeasts               | 6                              | 0                           | 6     |
| Novel foods          | 1                              | 1                           | 2     |
| Bacteria             | 1                              | 1                           | 2     |
| Plant protection products | 0                  | 0                           | 0     |
| Food enzymes, food additives and flavourings | 1 | 2 | 3 |
| Bacteria             | 1                              | 1                           | 2     |
| Filamentous fungi    | 0                              | 1                           | 1     |
| Total                | 30                             | 15                          | 48    |

QPS: qualified presumption of safety.

(a): The number includes filamentous fungi or enterococci excluded from QPS evaluation in the 2013 QPS Opinion, other bacterial species (seven notifications of E. coli, one of Streptomyces spp. and two of Enterococcus faecium) already excluded in the Panel Statement adopted in December 2016 (EFSA BIOHAZ Panel, 2017a).

Table 2: Flow of records by search strategy

| Species                          | Title screening step**** | Title/abstract screening step**** | Article evaluation step (screening for potential relevance) | Article evaluation step (identification of potential safety concerns) |
|----------------------------------|--------------------------|----------------------------------|------------------------------------------------------------|---------------------------------------------------------------------|
| Bacteria                         | 1,750                    | 57                               | 23                                                         | 14                                                                  |
| Bacillus spp.                    | 537                      | 3                                | 2                                                          | 1                                                                   |
| Bifidobacterium spp.             | 168                      | 17                               | 6                                                          | 1                                                                   |
| Carnobacterium diversgens        |                          |                                  | 0                                                          |                                                                      |
| Corynebacterium glutamicum       | 47                       | 0                                | 0                                                          | 0                                                                   |
| Gluconobacter oxydans            | 132                      | 2                                | 0                                                          | 0                                                                   |
| Xanthomonas campestris           |                          |                                  | 1                                                          | 0                                                                   |
| Lactobacillus spp.               | 426                      | 13                               | 7                                                          | 7                                                                   |
| Lactococcus lactis               | 152                      | 9                                | 4                                                          | 4                                                                   |
| Leuconostoc spp.                 | 44                       | 9                                | 3                                                          | 1                                                                   |
| Microbacterium imperiale         |                          |                                  | 0                                                          | 0                                                                   |
3. Assessment

3.1. Taxonomic Units evaluated during the previous QPS mandate and re-evaluated in the current Statement

3.1.1. Pseudomonas fluorescens

*P. fluorescens* has been previously evaluated and was not included in the QPS list (EFSA BIOHAZ Panel, 2017a).

3.1.1.1. Identity

Since the last update on the QPS status (EFSA BIOHAZ Panel, 2016) no new information on the taxonomy of *P. fluorescens* has been published.

3.1.1.2. Body of knowledge

*P. fluorescens* is a ubiquitous bacterium commonly encountered in aquatic, aerial, and soil matrices, as well as on rhizospheres and surfaces of plants, and also colonises mammalian hosts (Bergsma-Vlami et al., 2005; Dickson et al., 2014).

This metabolically versatile species produces a large number of secondary metabolites enabling it to succeed in competing with other microorganisms, and also making it of interest for biotechnology applications, namely, for use as a plant-growth promoter. Rhizosphere-inhabiting *P. fluorescens* produces compounds with antimicrobial activities (e.g. pyrrolnitrin) (Ramette et al., 2003; Mavrodi et al., 2006), which might contribute to natural plant protection from phytopathogens. Moreover, the production of mupirocin, used for prevention of methicillin-resistant *Staphylococcus aureus* infections, is also attributed to *P. fluorescens* (Sutherland et al., 1985; Villiger et al., 1986; Umio et al., 1987; Ligon et al., 2000).
3.1.1.3. Safety concerns

In humans, *P. fluorescens* has long been considered to be an opportunistic pathogen, involved in acute nosocomial infections. Most of those infections are iatrogenic, affect the bloodstream, and are attributable to the use of contaminated equipment used for intravenous infusion (Oba et al., 2017). In fact, it is considered as a platelet transfusion-relevant microorganism by WHO (Spindler-Raffel et al., 2017). While significantly less virulent than *P. aeruginosa*, different features of *P. fluorescens* have been associated with the ability to cause disease in humans (e.g. production of haemolysins, siderophores, type III secretion system and the ability to form biofilms) (Scales et al., 2014; Mazurier et al., 2015).

3.1.1.4. Antimicrobial resistance aspects

*P. fluorescens* can present antimicrobial resistance due to intrinsic and acquired antimicrobial resistance mechanisms (EFSA, 2007a). No new relevant information on AMR has been described.

3.1.1.5. Conclusions on a recommendation for the QPS list

The revision of the literature supports the previous identified safety concerns (e.g. production of biocompounds with antimicrobial activity and virulence features), preventing the inclusion of *P. fluorescens* in the QPS list.

3.2. Taxonomic Units to be evaluated for the first time

3.2.1. *Mycobacterium setense*

3.2.1.1. Identity

*M. setense* is a member of the *Mycobacterium fortuitum* complex, being more closely related, based on the sequence of the 16S rRNA gene, to *Mycobacterium houstonense* and *Mycobacterium senegalense* and on the sequence of the *rpoB* gene, to *Mycobacterium conceptionense*.

3.2.1.2. Body of knowledge

It is recognised that non-tuberculous mycobacteria are ubiquitously distributed in the environment, where they can be isolated from water and soil (Tortoli, 2014). Nevertheless, there is a paucity of data regarding this species’ habitat. Recently, a strain from this species (strain Manresensis) that was isolated from river water was claimed to delay tubercle bacilli colonisation into open tuberculosis in laboratory animals when used after heat-inactivation (Cardona et al., 2015; Tukvadze et al., 2016). A trial on human healthy volunteers seemed to indicate that its oral administration was safe in the short term (Montané et al., 2017).

3.2.1.3. Safety concerns

*M. setense* is part of the *M. fortuitum* complex, which is well known for its ability to cause skin, bone and joint infections (Yu et al., 2013) and mycolic acids of mycobacteria are recognised to induce granulomatous lesions (Fujita et al., 2007).

3.2.1.4. Antimicrobial resistance aspects

No information is available in the scientific literature.

3.2.1.5. Conclusions on a recommendation for the QPS list

*M. setense* cannot be considered a suitable microorganism species for the QPS status because there are significant safety concerns.

3.2.2. *Komagataeibacter sucrofermentans*

3.2.2.1. Identity

The bacterial species, *K. sucrofermentans* (Validation List nr. 149, IJSM 2013, 63, 1-5) was previously named *Acetobacter xylinus* subsp. *sucrofermentans* (Toyosaki et al., 1996) and *Gluconacetobacter sucrofermentans* (Cleenwerck et al., 2010). The species is clearly described based on a polyphasic approach (Cleenwerck et al., 2010).
3.2.2.2. Body of knowledge

*K. sucrofermentans* strains are characterised by their ability to produce large amounts of cellulose from sucrose in agitated cultures (Cleenwerck et al., 2010). Searching PubMed database for this species delivered 11 hits, all concerning the cellulose production capacity. In Asia, cellulose has traditionally been produced from the fermentation of coconut waste-water by *K. sucrofermentans* and used in food.

3.2.2.3. Safety concerns

No safety concerns were reported by using *K. sucrofermentans*.

3.2.2.4. Antimicrobial resistance aspects

No information is available.

3.2.2.5. Conclusions on a recommendation for the QPS list

*K. sucrofermentans* (*A. xylinus* subsp. *sucrofermentans*) can be proposed for the QPS list but only for production purposes.

3.2.3. Extension of qualification of *Corynebacterium glutamicum*

*C. glutamicum* has been recommended for the QPS status but the qualification has only been applied when the species is used for aminoacid production. In the meantime, notifications arrived to EFSA for other production purposes and it was requested from EFSA units to extend the qualification to other uses.

*C. glutamicum* does not produce known toxic compounds. Consequently, there is no hazard related to the presence of toxic metabolites in the fermentation broth.

The QPS status of *C. glutamicum* is confirmed with the qualification extended to other production purposes.

3.3. Monitoring of new safety concerns related to organisms on the QPS list

The summaries of the evaluation of the possible safety concerns for humans, animals or the environment caused by QPS organisms described and published since the previous evaluation (i.e. ELS search run between January and June 2018, as described in Appendices B and C) are presented below. The references selected as potentially relevant for the QPS exercise are included in Appendix D for each of the TUs or groups of TUs that are part of the QPS list (Appendix E). As already explained in 2.2.2, for practical reasons, some TUs were grouped for the screening steps.

3.3.1. Gram-positive non-sporulating bacteria

3.3.1.1. *Bifidobacterium* spp.

Search of papers potentially relevant for the QPS consideration of *Bifidobacterium* spp. and *Carnobacterium divergens* provided 168 references. The analysis of their titles led 17 articles for consideration; the rest were discarded because they did not deal with safety concerns. Six articles were found relevant for the QPS consideration of *Bifidobacterium* spp. at the level of title and abstract screening (de Andres et al., 2018; Downes et al., 2018; Kim et al., 2018a; Kumar et al., 2018; Martínez et al., 2018). After screening the entire papers, five of them were finally discarded because they did not deal with safety concerns. The paper of Martínez et al. (2018) was kept because the authors identified and characterised a novel gene, homolog to rRNA methylases, which confers erythromycin and clindamycin resistance that can be found in some strains of *Bifidobacterium* spp.

Based on the available evidence as described above, the QPS status of *Bifidobacterium* spp. is not changed.

3.3.1.2. *Carnobacterium divergens*

Search of papers potentially relevant for the QPS consideration of *Bifidobacterium* spp. and *Carnobacterium divergens* provided 168 references. The analysis of their titles led 17 articles for consideration; the rest were discarded because they did not deal with safety concerns. No article arrived to the final stage for this TU. Consequently, the QPS status of *C. divergens* is not changed.
3.3.1.3. Corynebacterium glutamicum

Search of papers potentially relevant for the QPS consideration of Corynebacterium glutamicum provided 47 references. No paper reached the final selection phase, so no new safety concern was found.

In parallel to the standard procedure for assessing a TU for a possible QPS status and to the maintenance of a QPS status, it was decided to run a complementary reassessment for another specific end-use of this TU as the QPS qualification ‘only applies when the species is used for amino acid production’. The QPS status of Corynebacterium glutamicum is confirmed with the qualification extended to other production purposes.

3.3.1.4. Lactobacillus spp.

Search of papers potentially relevant for the QPS consideration of any of the 35 Lactobacillus species included in the list, provided 426 references. Analysis of their titles left 13 articles for consideration; the rest were discarded because they did not deal with safety concerns. Analysis of the abstracts of these allowed the selection of seven papers that raised safety concerns (Biesiada et al., 2018; Boumis et al., 2018; García Carretero et al., 2018; Harding-Theobald and Maraj, 2018; Kane et al., 2018; Koyama et al., 2018; de Seynes et al., 2018). Single papers dealt with infections by L. casei (de Seynes et al., 2018), L. plantarum (Biesiada et al., 2018), L. paracasei (Harding-Theobald and Maraj, 2018), L. salivarius (García Carretero et al., 2018) and there were three on L. rhamnosus (Boumis et al., 2018; Kane et al., 2018; Koyama et al., 2018).

There were methodological shortcomings on the L. casei and L. plantarum identifications (both were done by just phenotypical methods) (Biesiada et al., 2018; de Seynes et al., 2018). All articles involved single cases of infection of patients that suffered from predisposing illnesses such as metastatic lung cancer (Biesiada et al., 2018), haemorrhagic telangiectasia (Boumis et al., 2018), alcoholic cirrhosis (Harding-Theobald and Maraj, 2018), anastomotic leak from a bariatric surgery (García Carretero et al., 2018), osteoarthritis (de Seynes et al., 2018) or were immunocompromised after having received a bone marrow transplant (Koyama et al., 2018).

Based on the available evidence as described above, the QPS status of the lactobacilli involved in the reported cases and, by extension, of all others included in the QPS list is not changed.

3.3.1.5. Lactococcus lactis

Search of papers potentially relevant for the QPS consideration of Lactococcus lactis provided 152 references. Analysis of their titles left nine articles for consideration; the rest were discarded because they did not deal with safety concerns. Analysis of the abstracts allowed selection of four papers that raised safety concerns (Georgountzos et al., 2018; Mussano et al., 2018; Tato Rodríguez et al., 2018; Wünemann et al., 2018). Three of them described cases of human endocarditis (Georgountzos et al., 2018; Tato Rodríguez et al., 2018) and oral lesions (Mussano et al., 2018) while the fourth described infection of the fish Alosa alosa.

However, there was no indication on how the identification of the causal organism was done in the case described by Georgountzos et al. (2018), and the paper by Mussano et al. (2018) reported a polymicrobial infection from which more than 25 bacterial species were identified, including well known pathogens, which makes the lactococcal aetiology of the lesions doubtful. The endocarditis case presented by Tato Rodríguez et al. (2018) affected an 80-year-old man that presented predisposing conditions; namely, previous valve replacement and aortocoronary bypass. Finally, the fish studied by Wünemann et al. (2018) had been recently captured from the wild and kept in an overpopulated tank under very low oxygen concentrations, conditions described by the authors as very stressful.

Based on the available evidence as described above, the QPS status of Lactococcus lactis is not changed.

3.3.1.6. Leuconostoc spp.

Search of papers potentially relevant for the QPS consideration of Leuconostoc and Microbacterium imperial provided 44 references. The analysis of their titles left nine articles for consideration; the rest were discarded because they did not deal with safety concerns. Most of these nine papers lacked information on the identification procedures used to identify the infectious agents. Three papers arrived to the full text phase. Two were immediately excluded as they were not dealing with these TUs. One paper, Lin et al. (2018) arrived to the final stage of the evaluation. This study describes a case of hemophagocytic lymphohistiocytosis with Leuconostoc pseudomesenteroides bacteraemia in a
33-year-old man with a previous medical history including unexplained anaemia and splenomegaly. The identification of *L. pseudomesenteroides* from the blood cultures was achieved by phenotypic testing. The infections reported were extremely rare and the affected patients already suffered from debilitating illnesses.

Based on the available evidence as described above, there is no need to change the QPS recommendation of *L. pseudomesenteroides* and of other *Leuconostoc* species included in the QPS list.

### 3.3.1.7. *Microbacterium imperiale*

Search of papers potentially relevant for the QPS consideration of *Leuconostoc* and *Microbacterium imperiale* provided 44 references. The analysis of their titles left nine articles for consideration; the rest were discarded because they did not deal with safety concerns. Most of these nine papers lacked information on the identification procedures used to identify the infectious agents. Three papers arrived to the full text phase but were immediately excluded as they were not dealing with this TU. Consequently, the QPS status of *M. imperiale* is not changed.

### 3.3.1.8. *Oenococcus oeni*

Search of papers potentially relevant for the QPS consideration of *Oenococcus oeni* and *Pasteuria nishizawai* provided 43 references. The analysis of their titles did not leave any articles for consideration. As no paper reached the final selection phase, no new safety concern was found. Consequently, the QPS status of *O. oeni* is not changed.

### 3.3.1.9. *Pasteuria nishizawai*

Search of papers potentially relevant for the QPS consideration of *Oenococcus oeni* and *Pasteuria nishizawai* provided 43 references. The analysis of their titles did not leave any articles for consideration. As no paper reached the final selection phase, no new safety concern was found. Consequently, the QPS status of *P. nishizawai* is not changed.

### 3.3.1.10. *Pediococcus* spp.

Search of papers potentially relevant for the QPS consideration of *Pediococcus* spp. provided 126 references. The analysis of their titles left one single article for consideration that did not reach the final selection phase; so, no new safety concern was found. Consequently, the QPS status of *Pediococcus* spp. is not changed.

### 3.3.1.11. *Propionibacterium* spp.

Search of papers potentially relevant for the QPS consideration of *Propionibacterium* spp. provided 30 references. The analysis of their titles left one single article for consideration that did not reach the final selection phase; so, no new safety concern was found. Consequently, the QPS status of *Propionibacterium* spp. is not changed.

### 3.3.1.12. *Streptococcus thermophilus*

Search of papers potentially relevant for the QPS consideration of *Streptococcus thermophilus* provided 45 references. The analysis of their titles left two articles for consideration that did not reach the final selection phase; so, no new safety concern was found. Therefore, the QPS status of *S. thermophilus* is not changed.

### 3.3.2. Gram-positive spore-forming bacteria

#### 3.3.2.1. *Bacillus* spp.

Search of papers potentially relevant for the QPS consideration of *Bacillus* spp. and *Geobacillus stearothermophilus* provided 537 references. The analysis of their titles left three articles for consideration; the rest were discarded because they did not deal with safety concerns.

Two papers concerning *Bacillus* spp. reached the final selection phase and were analysed in-depth (Kim et al., 2018b; Tran et al., 2018). Tran et al. (2018) paper was excluded because there was not enough information (conference proceedings). The work of Kim et al. (2018b), describing a case of a pyometra in an immunosuppressed dog, presented several methodological shortcomings and therefore the data presented were not included in the current assessment.

The ELS did not come up with any information that would change the status of the *Bacillus* species included in the QPS list.
3.3.2.2. *Geobacillus stearothermophilus*

Search of papers potentially relevant for the QPS consideration of *Bacillus* spp. and *Geobacillus stearothermophilus* provided 537 references. The analysis of their titles left three articles for consideration; none of them were related to this TU. Consequently, the QPS status *Geobacillus stearothermophilus* is not changed.

3.3.3. Gram-negative bacteria

3.3.3.1. *Gluconobacter oxydans*

Search of papers potentially relevant for the QPS consideration of *Gluconobacter oxidans* and *Xanthomonas campestris* provided 132 references. The analysis of their titles left two articles for consideration; the rest were discarded because they did not deal with safety concerns. No paper reached the final selection phase for this TU. Consequently, the QPS status of *G. oxydans* is not changed.

3.3.3.2. *Xanthomonas campestris*

Search of papers potentially relevant for the QPS consideration of *Gluconobacter oxidans* and *Xanthomonas campestris* provided 132 references. The analysis of their titles left two articles for consideration; the rest were discarded because they did not deal with safety concerns. One paper (Sundin and Wang, 2018) reached the final selection phase. It was excluded because it does not deal with safety concerns. Consequently, the QPS status of *X. campestris* is not changed.

3.3.4. Yeasts

Search of papers potentially relevant for the QPS consideration of the yeasts’ species included in the QPS list provided 1,210 references.

Thirty-five papers reached the final step of the ELS. Fourteen of these were immediately excluded because they were not in English or because they were not dealing with safety concerns. Thus, the ELS identified 21 articles relevant for the different yeast species with QPS status (please refer to Appendix D for the complete list of references).

For 6 (Kumari et al., 2018; Mohamed et al., 2018; Rajkowska and Kunicka-Styczyńska, 2018; Vieira et al., 2018; Yang and Mao, 2018; Yenisehirli et al., 2018) of these 21 references, the value of the results and conclusions presented were very limited due to a weaknesses in the methodology used for identity confirmation of the microorganism in all references, to a lack of information regarding the source attribution in three of them (Rajkowska and Kunicka-Styczyńska, 2018; Yenisehirli et al., 2018) or to predisposing factors in the exposed subject (Yang and Mao, 2018).

From the remaining 15 references that describe a safety concern, 13 were related to human health (Al-Tekreeti et al., 2018; Aslani et al., 2018; Charsizadeh et al., 2018a,b,c; Jahanshiri et al., 2018; Nejat et al., 2018; Ortiz et al., 2018; Sav et al., 2018; Scapaticci et al., 2018; Siavoshi et al., 2018; Taverna et al., 2018; Wasilewska and Wroblewska, 2018); one to animal health (Dangarembizi et al., 2018) and four to antimicrobial resistance (Sav et al., 2018; Scapaticci et al., 2018; Sekyere and Asante, 2018; Taverna et al., 2018).

Out of these 15 papers describing a safety concern for one or several QPS yeast species, 10 referred to *Candida kefyr* (teleomorph = *Kluveromyces marxianus*) (Al-Tekreeti et al., 2018; Aslani et al., 2018; Charsizadeh et al., 2018a,b,c; Jahanshiri et al., 2018; Nejat et al., 2018; Ortiz et al., 2018; Sav et al., 2018; Scapaticci et al., 2018)), five to *Saccharomyces cerevisiae* of which one was identified as *Saccharomyces boulardii* (Aslani et al., 2018; Dangarembizi et al., 2018; Scapaticci et al., 2018; Sekyere and Asante, 2018; Wasilewska and Wroblewska, 2018)), five to *Candida famata* (teleomorph = *Debaryomyces hansenii*) (Kumari et al. (2018); (Mohamed et al., 2018; Rajkowska and Kunicka-Styczyńska, 2018; Taverna et al., 2018; Vieira et al., 2018) and one to *Hanseniaspora uvarum* (Siavoshi et al., 2018).

*S. cerevisiae/S. boulardii, C. famata and H. uvarum* were reported to be very occasionally (up to four studies) associated with fungal and nosocomial infections in immunocompromised or post-surgery patients. However, 10 studies referred to *C. kefyr/K. marxianus*. The last one has received increased attention in recent years, but reports where it has been unambiguously shown to be causative agent of infectious disease in otherwise healthy individuals are very rare. There is reason to closely follow whether there is a tendency for *C. kefyr/K. marxianus* to become more common in this kind of infection.

For the other yeast species with QPS status, no relevant studies were identified through the ELS.

In short, the ELS did not identify with any information that would change the status for the yeast species included in the QPS list.
3.3.5. Viruses used for plant protection

The ELS did not come up with any information that would change the current QPS status of any of the virus families.

3.3.5.1. Alphaflexiviridae

Search of papers potentially relevant for the QPS consideration of Alphaflexiviridae provided 26 references. No paper reached the final selection phase, so no new safety concern was found.

3.3.5.2. Baculoviridae

Search of papers potentially relevant for the QPS consideration of Baculoviridae provided 48 references. The analysis of their titles left one single article for consideration that did not reach the final selection phase, so no new safety concern was found.

4. Conclusions

ToR 1: Keep updated the list of biological agents being notified, in the context of a technical dossier to EFSA Units (such as Feed, Food Ingredients and Packaging (FIP), Nutrition Unit and Pesticides Unit), for intentional use in feed and/or food or as sources of food and feed additives, enzymes and plant protection products for safety assessment:

- Between April and September 2018, the list was updated with 48 notifications that were received by EFSA, of which 41 were for feed additives, three for food enzymes, food additives and flavourings, four for novel foods and none for plant protection products.

ToR 2: Review taxonomic units previously recommended for the QPS list and their qualifications when new information has become available:

- In relation to the results of the monitoring of possible new safety concerns related to the QPS list, there were no results that justify removal of any TU from the QPS list or changes in their respective qualifications.

ToR 3: (Re)assess the suitability of taxonomic units notified to EFSA not present in the current QPS list for their inclusion in that list:

- The TUs corresponding to 30 out of the 48 notifications received, already had a QPS status.
- The TUs corresponding to 15 out of the 18 notifications without a QPS status were: five notifications related to filamentous fungi which were excluded from QPS activities in the follow-up of a recommendation of the QPS 2013 update (EFSA BIOHAZ Panel, 2013, 2014, 2016), seven notification related to E. coli, one to Streptomyces spp. and two to Enterococcus faecium, which were recently excluded from the current mandate by the BIOHAZ Panel (EFSA BIOHAZ Panel, 2018a).
- Three TUs, corresponding to the other three out of those 18 notifications, were evaluated for potential QPS recommendation: Pseudomonas fluorescens already evaluated in 2016 and not granted QPS status (EFSA BIOHAZ Panel, 2017a) was now re-evaluated within this mandate, Mycobacterium setense and Komagataeibacter sucrofermentans, both evaluated here for the first time.

5. Recommendations

- The revision of the literature supports the previous identified safety concerns (e.g. production of biocompounds with antimicrobial activity and virulence features), preventing the inclusion of P. fluorescens in the QPS list.
- M. setense cannot be considered for the QPS assessment because there are significant safety concerns.
- K. sucrofermentans (A. xylinus subsp. sucrofermentans) can be proposed for the QPS list but only for production purposes.
- The QPS status of Corynebacterium glutamicum is confirmed with the qualification extended to other production purposes.

This new QPS recommendation will be included as an addition to the list of QPS status recommended biological agents (EFSA BIOHAZ Panel, 2016), published both as an update to the Scientific Opinion (EFSA BIOHAZ Panel, 2016) and as supporting information available on the Knowledge Junction at https://doi.org/10.5281/zenodo.1146566.
References

Al-Tekreeti ARA, Al-Halbousi MMF, Dheeb BJ, Hashim AJ, Al-Zuhairi AFH and Mohammad FI, 2018. Molecular identification of clinical Candida isolates by simple and randomly amplified polymorphic DNA-PCR. Arabian Journal for Science and Engineering, 43, 163–170.

deAndres J, Jimenez E, Chico-Calero I, Fresno M, Fernandez L and Miguel Rodriguez J, 2018. Physiological translocation of lactic acid bacteria during pregnancy contributes to the composition of the milk microbiota in mice. Nutrients. 10. https://doi.org/10.3390/nu10010014

Aslani N, Jannbabaei G, Abastabar M, Meis JF, Babaieian M, Khodavaisy S, Boekhout T and Badali H, 2018. Identification of uncommon oral yeasts from cancer patients by MALDI-TOF mass spectrometry. BMC Infectious Diseases, 18.

Bergsma-Vlami M, Prins ME and Raaijmakers JM, 2005. Influence of plant species on population dynamics, genotypic diversity and antibiotic resistance production in the rhizosphere by indigenous Pseudomonas spp. FEMS Microbiology Ecology, 52, 59–69. https://doi.org/10.1016/j.femsec.2004.10.007

Biesiada G, Krycinska R, Czepiel J, Stazyk K, Kedzierska J and Garlicki A, 2018. Meningoencephalitis caused by Lactobacillus plantarum - case report. International Journal of Neuroscience, 1–9. https://doi.org/10.1080/00207454.2018.1482293

Boumis E, Capone A, Galati V, Venditti C and Petrosillo N, 2018. Probiotics and infective endocarditis in patients with hereditary hemorrhagic telangiectasia: a clinical case and a review of the literature. BMC Infectious Diseases, 18, 65. https://doi.org/10.1186/s12879-018-2956-5

Cardona P, Marzo-Escartin E, Tapia G, Diaz J, Garcia V, Varela I, Vilaplana C and Cardona PJ, 2015. Oral administration of heat-killed Mycobacterium marneffensis delays progression toward active tuberculosis in C3HeB/FeJ mice. Frontiers in Microbiology, 6, 1482. https://doi.org/10.3389/fmicb.2015.01482

Charsizadeh A, Mirhendi H, Nikmanesh B, Eshaghi H and Makimura K, 2018a. Candidemia in children caused by uncommon species of Candida. Archives of Pediatric Infectious Diseases, 6.

Charsizadeh A, Nikmanesh B, Ahmadi B, Jalalizand N, Safarzi N, Rahmani M, Kordbacheh P and Mirhendi H, 2018c. Frequency of Candida species isolated from patients in Children’s Medical Center, Tehran, Iran. Archives of Pediatric Infectious Diseases, 6.

Cleenwerck I, De Vos P and De Vuyst L, 2010. Phylogeny and differentiation of species of the genus Gluconacetobacter and related taxa based on multilocus sequence analyses of housekeeping genes and reclassification of Acetobacter xylinus subsp. sucrofermentans as Gluconacetobacter sucrofermentans (Toyosaki et al. 1996) sp. nov., comb. nov. International Journal of Systematic and Evolutionary Microbiology, 60, 2277–2283. https://doi.org/10.1099/ijs.0.018465-0

Dangarembizi R, Erlwanger KH, Rummel C, Roth J, Madziva MT and Harden LM, 2018. Brewer’s yeast is a potent inducer of fever, sickness behavior and inflammation within the brain. Brain Behavior and Immunity, 68, 211–223.

Dickson RP, Erb-Downward JR, Freeman CM, Walker N, Scales BS, Beck JM, Martinez FJ, Curtis JL, Lama VN and Huffnagle GB, 2014. Changes in the lung microbiome following lung transplantation include the emergence of two distinct Pseudomonas species with distinct clinical associations. PLoS ONE, 9, e97214. https://doi.org/10.1371/journal.pone.0097214

Downes KL, Ravel J, Gajer P and Elovitz MA, 2018. Specific microbes present in the early third trimester in the cervicovaginal space are associated with spontaneous labor at term. American Journal of Obstetrics and Gynecology, 218, S239–S240.

EFSA (European Food Safety Authority), 2005. Opinion of the Scientific Committee on a request from EFSA related to a generic approach to the safety assessment by EFSA of microorganisms used in food/feed and the production of food/feed additives. EFSA Journal 2005;3(4):226, 12 pp. https://doi.org/10.2903/j.efsa.2005.226

EFSA (European Food Safety Authority), 2007a. Introduction of a Qualified Presumption of Safety (QPS) approach for assessment of selected microorganisms referred to EFSA - Opinion of the Scientific Committee. EFSA Journal 2007;5(12):587, 16 pp. https://doi.org/10.2903/j.efsa.2007.587

EFSA (European Food Safety Authority), 2008. Scientific Opinion of the Panel on Biological Hazards on the maintenance of the list of QPS microorganisms intentionally added to food or feed. EFSA Journal 2008;6(12):923, 48 pp. https://doi.org/10.2903/j.efsa.2008.923

EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards), 2009. Scientific Opinion on the maintenance of the list of QPS microorganisms intentionally added to food or feed (2009 update). EFSA Journal 2009;7(12):1431, 92 pp. https://doi.org/10.2903/j.efsa.2009.1431

EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards), 2013. Scientific Opinion on the maintenance of the list of QPS biological agents intentionally added to food and feed (2013 update). EFSA Journal 2013;11(11):3449, 108 pp. https://doi.org/10.2903/j.efsa.2013.3449

EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards), 2014. Statement on the update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 1: suitability of taxonomic units notified to EFSA until October 2014. EFSA Journal 2014;12(12):3938, 41 pp. https://doi.org/10.2903/j.efsa.2014.3938

www.efsa.europa.eu/efsajournal 17

EFSA Journal 2019;17(1):SSSS
EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards), 2016. Statement on the update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 4: suitability of taxonomic units notified to EFSA until March 2016. EFSA Journal 2016;14(7):4522, 37 pp. https://doi.org/10.2903/j.efsa.2016.4522

EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards), 2018. Spontaneous bacterial peritonitis due to Lactobacillus salivarius infection as a postoperative complication after bariatric surgery. Enfermedades Infecciosas Y Microbiologia Clinica, 36, 60–61. https://doi.org/10.1016/j.eimc.2017.03.011

Georgountzos G, Michopoulos C, Grivokostopoulos C, Kolosaka M, Vlassopoulou N and Lekkou A, 2018. Infective endocarditis in a young adult due to Lactococcus lactis: a case report and review of the literature. Case Reports in Medicine, 2018, Article ID 5091456. https://doi.org/10.1155/2018/5091456

Garcia Carretero R, Regodon Dominguez M, Ruiz Bastian M and Lopez Lomba M, 2018. Lactobacillus salivarius infection as a postoperative complication after bariatric surgery. Enfermedades Infecciosas Y Microbiologia Clinica, 36, 60–61. https://doi.org/10.1016/j.eimc.2017.03.011

Georgountzos G, Michopoulos C, Grivokostopoulos C, Kolosaka M, Vlassopoulou N and Lekkou A, 2018. Infective endocarditis in a young adult due to Lactococcus lactis: a case report and review of the literature. Case Reports in Medicine, 2018, Article ID 5091456. https://doi.org/10.1155/2018/5091456

Harding-Theobald E and Maraj B, 2018. Spontaneous bacterial peritonitis due to Lactobacillus salivarius infection as a postoperative complication after bariatric surgery. Enfermedades Infecciosas Y Microbiologia Clinica, 36, 60–61. https://doi.org/10.1016/j.eimc.2017.03.011

Jahanshiri Z, Manifar S, Moosa H, Asghari-Paskiabi F, Mahmoodzadeh H, Shams-Ghahfarokhi M and Razzaghi-Ardakani, 2018. Septicemia from Clostridium perfringens, from a probiotic enriched Yogurt, in a patient with autologous stem cell transplantation. Probiotics and Antimicrobial Proteins. https://doi.org/10.1007/s12602-018-9399-6

Kim MJ, Ku S, Kim SY, Lee HH, Jin H, Kang S, Li R, Johnston TV, Park MS and Ji GE, 2018a. Safety evaluations of Bifidobacterium bifidum BGN4 and Bifidobacterium longum BORI. International Journal of Molecular Sciences, 19, 22. https://doi.org/10.3390/ijms19051422

Kim MK, Yoon HY, Lee MH and Kim JH, 2018b. Canine pyometra associated with Bacillus species: a case report. Veterinarni Medicina, 63, 143–149.

Koyama S, Fujita Y, Okamoto Y, Uenishi Y, Sunagawa M, Uchiyama T and Yano I, 2007. Molecular and supra-molecular structure related differences in toxicity and granulomatogenic activity of mycobacterial cord factor in mice. Microbial Pathogens, 43, 10–21. https://doi.org/10.1016/j.micpath.2007.02.006

Kumari S, Dey S, Sena A, Kumar D and Akhter K, 2018. Characterisation and antifungal susceptibility testing of Candida species isolated from clinical samples of patients attending Katihar Medical College, Katihar, Bihar. Journal of Evolution of Medical and Dental Sciences-JEMDS, 7, 662–666.
BIOHAZ statement on QPS: suitability of taxonomic units notified until September 2018

Ligon JM, Hill DS, Hammer PE, Torkekowitz NR, Hofmann D, Kempf H-J and van Pee K-H, 2000. Natural products with antifungal activity from Pseudomonas biocontrol bacteria. Pest Management Science, 56, 688-695. https://doi.org/10.1002/1526-4998(200008)56:8<688:AID-PS186>3.0.CO;2-V

Lin X, Jiang Q, Liu J, Zhao F and Chen W, 2018. Leuconostoc pseudomesserteroides-associated hemophagocytic syndrome: a case report. Experimental and Therapeutic Medicine, 15, 1199–1202.

Martinez N, Luque R, Milani C, Ventura M, Baruelos O and Margolles A, 2018. A gene homologous to rRNA methylase genes confers erythromycin and clindamycin resistance in Bifidobacterium breve. Applied and Environmental Microbiology, 84, Article Number: UNSP e02888-02817. https://doi.org/10.1128/AEM.02888-17

Mavrodi DV, Blankenfeldt W and Thomashow LS, 2006. Phenazine compounds in fluorescent Pseudomonas spp. biosynthesis and regulation. Annual Review of Phytopathology, 44, 417–445. https://doi.org/10.1146/annurev.v.phyto.44.013106.145710

Mazurek S, Merieau A, Bergeau D, Decoin V, Sperandio D, Crepin A, Barbey C, Jeannot K, Vicre-Gibouin M, Piesiat P, Lemanceau P and Latour X, 2017. Type III secretion system and virulence markers highlight similarities and differences between human- and plant-associated pseudomonads related to Pseudomonas fluorescens and P. putida. Applied and Environmental Microbiology, 81, 2579–2590. https://doi.org/10.1128/aem.04160-14

Mohamed NA, Pathmanathan SG, Hussin H and Zaini AB, 2018. Distribution and antifungal susceptibility pattern of Candida species at a Tertiary Hospital in Malaysia. Journal of Infection in Developing Countries, 12, 102–108.

Moher D, Liberati A, Tetzlaff J and Altman DG and PRISMA Group, 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine, 6, e1000097. https://doi.org/10.1371/journal.pmed.1000097

Montané E, Barriocanal AM, Arenallo AL, Valderrama A, Sanz Y, Perez-Alvarez N, Cardona P, Vilaplana C and Cardona PJ, 2017. Pilot, double-blind, randomized, placebo-controlled clinical trial of the supplement food Nyarditum resae(R) in adults with or without latent TB infection: safety and immunogenicity. PLoS ONE, 12, e0171294.

Mussano F, Ferrocino I, Gavrilova N, Genova T, Dell’Acqua A, Cocolin L and Carossa S, 2018. Apical periodontitis: preliminary assessment of microbiota by 16S rRNA high throughput amplicon target sequencing. BMC Oral Health, 18, Art. 55, 58 pp. https://doi.org/10.1186/s12903-018-0520-8

Nejat ZA, Farahyars F, Falahati M, Khozani MA, Hosseini AF, Faizy A, Ekhtiar M and Hashemi-Hafshenjani S, 2018. Molecular identification and antifungal susceptibility pattern of non-albicans Candida species isolated from vulvovaginal candidiasis. Iranian Journal of Medical Microbiology, 22, 33–41.

Oba Y, Nakajima T, Ogida C, Kawanami M, Fujiwara M and Matsumura I, 2017. Longitudinal nosocomial outbreak of Pseudomonas fluorescens bloodstream infection of 2 years’ duration in a coronary care unit. American Journal of Infection Control, 45, e75–e79. https://doi.org/10.1016/j.ajic.2017.05.008

Ortiz B, Perez-Aleman E, Galo C and Fontecha G, 2018. Molecular identification of Candida species from urinary infections in Honduras. Revista Iberoamericana De Micologia, 35, 73–77.

Rajkowska K and Kunicka-Styczynska A, 2018. Typing and virulence factors of food-borne Candida spp. isolates. International Journal of Food Microbiology, 279, 57–63. https://doi.org/10.1016/j.ijfoodmicro.2018.05.002

Ramette A, Moenne-Loccoz Y and Defago G, 2003. Prevalence of fluorescent pseudomonads producing antifungal phloroglucinols and/or hydrogen cyanide in soils naturally suppressive or conducive to tobacco black root rot. FEMS Microbiology Ecology, 44, 35–43. https://doi.org/10.1016/S0168-6496(02)00454-3

Sav H, Baris A, Turan D, Altinbas R and Sen S, 2018. The frequency, antifungal susceptibility and enzymatic profiles of Candida species in cases of onychomycosis infection. Microbial Pathogenesis, 116, 257–262. https://doi.org/10.1016/j.micpath.2018.01.036

Scales BS, Dickson RP, LiPuma JJ and Huffnagle GB, 2014. Microbiology, genomics, and clinical significance of the Pseudomonas fluorescens species complex, an unappreciated colonizer of humans. Clinical Microbiology Reviews, 27, 927–948. https://doi.org/10.1128/cmrr.00044-14

Scapaticci M, Bartolini A, Del Chierico F, Accardi C, Di Girolamo F, Masotti A, Muraca M and Putignani L, 2018. Phenotypic typing and epidemiological survey of antifungal resistance of Candida species detected in clinical samples of Italian patients in a 17 months’ period. Germs, 8, 58–66.

Sekyere JO and Asante J, 2018. Emerging mechanisms of antimicrobial resistance in the era of genomics. Future Microbiology, 13, 241–262.

de Seynes C, Dutronc H, Cremer P and Dupon M, 2018. Lactobacillus casei prosthetic joint infection. Médecine et Maladies Infectieuses, 48, 422–430. https://doi.org/10.1016/j.medical.2018.04.390

Siavoshi F, Sahraee M, Ebrahimi H, Sarrafnejad A and Saniee P, 2018. Natural fruits, flowers, honey, and honeybees harbor Helicobacter pylori-positive yeasts. Helicobacter, 23, e12471, 12411 pp. https://doi.org/10.1111/11.1(12471

Spindler-Raffel E, Benjamin RJ, McDonald CP, Ramirez-Arcos S, Aplin K, Bekeredjian-Ding I, de Korte D, Gabriel C, Gathof B, Hanschmann KM, Hourkarf I, Ingram C, Jacobs MR, Keil SD, Kou Y, Lambrecht B, Marcelis J, Mukhtar Z, Nagan H, Niekert K, Rojo J, Marschner S, Satake M, Seltsam A, Seifried E, Sharafat S, Stormer M, Sussner S, Wagner SJ and Yomtovian R and SBT Working Party Transfusion-Transmitted Infectious Diseases (WP-TTID) - Subgroup on Bacteria, 2017. Enlargement of the WHO international repository for platelet transfusion-relevant bacteria reference strains. Vox Sanguini, 112, 713–722. https://doi.org/10.1111/vox.12458

www.efsa.europa.eu/efsajournal 19 EFSA Journal 2019;17(1):6555
Sundin GW and Wang N, 2018. Antibiotic resistance in plant-pathogenic bacteria. Annual Review of Phytopathology, 56, 161–180. https://doi.org/10.1146/annurev-phyto-080417-045946

Sutherland R, Boon RJ, Griffin KE, Masters PJ, Slocombe B and White AR, 1985. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrobial Agents and Chemotherapy, 27, 495–498.

Tato Rodríguez R, Guzmán Figueroa DM, Trigo Daporta M and García Campello M, 2018. Fever in an 80-year-old male carrying biologic aortic prosthesis endocarditis due to Lactococcus lactis subsp. lactis. Journal of Clinical Microbiology, 56, e03357-03315, 03352. https://doi.org/10.1128/JCM.03357-15

Taverna CG, Córdoba S, Vivot M, Szusz W, Vivot W, Bosco-Borgeat ME and Davel G, 2018. Reidentification and antifungal susceptibility profile of Candida guilliermondii and Candida famata clinical isolates from a culture collection in Argentina. Medical Mycology, myy038. https://doi.org/10.1093/mmy/myy038

Tortoli E, 2014. Microbiological features and clinical relevance of new species of the genus Mycobacterium. Clinical Microbiology Reviews, 27, 727–752. https://doi.org/10.1128/CMR.00035-14

Toyosaki H, Kojima Y, Tsuchida T, Hoshino K, Yamada Y and Yoshinaga F, 1996. Acetobacter xylinum subsp. sucrorеsеntаs subsp. nov. In Validation of the publication of new names and new combinations previously effectively published outside the IJSB, List no. 58. International Journal of Systematic and Evolutionary Microbiology, 46, 836–837.

Tran TT, Varghese M and Baer S, 2018. Polymicrobial Endocarditis caused by Abiotrophia defectiva, Bacillus cereus, Bacillus subtilis and Bacillus megaterium in the setting of injection drug use. Journal of Investigative Medicine, 66, 473. https://doi.org/10.1159/000079988

Wasilewska E and Wroblewska B, 2018. Effectiveness and safety of probiotic preparations in clinical treatment of inflammatory bowel disease. Postepy Higieny I Medycyny Doswiadczalnej, 72, 159–174.

Wünnemann H, Eskens U, Prenger-Berninghoff E, Ewers C and Lierz M, 2018. Lactococcus lactis, causative agent of an endocarditis valvularis and parietalis thromboticans in the allis shad, Alosa alosa (L.). Journal of Fish Diseases. https://doi.org/10.1111/jfd.12813

Yang Y-C and Mao J, 2018. Value of platelet count in the early diagnosis of nosocomial invasive fungal infections in premature infants. Platelets, 29, 65–70. https://doi.org/10.1080/09537104.2017.1293810

Yu JR, Heo ST, Lee KH, Kim J, Sung JK, Kim YR and Kim JW, 2013. Skin and soft tissue infection due to rapidly growing mycobacteria: case series and literature review. Infection and Chemotherapy, 45, 85–93. https://doi.org/10.3947/ic.2013.45.1.85

Glossary and Abbreviations

AMR antimicrobial resistance
BIOHAZ EFSA Panel on Biological Hazards
ELS extensive literature search
FIP EFSA Food ingredients and packaging Unit
FSTA Food Science Technology Abstracts
GMM genetically modified microorganisms
QPS qualified presumption of safety
PPP plant protection product
ToR Term of Reference
TU taxonomic unit
WG Working Group

www.efsa.europa.eu/efsajournal 20 EFSA Journal 2019;17(1):5555
Appendix A – Search strategy followed for the (re)assessment of the suitability of TUs notified to EFSA not present in the current QPS list for their inclusion in the updated list (reply to ToR 3)

Pseudomonas fluorescens

A literature search was performed in PubMed database, using the search terms “Pseudomonas fluorescens” AND (“infection” OR “risk”), from 2016: 41 hits were identified and screened. Another search was done in Web of Science using the search terms “Pseudomonas fluorescens” AND “infection”: 94 hits were identified and screened.

Mycobacterium setense

A literature search was performed in the Web of Science, using the search term “Mycobacterium setense”, from 2016: three hits were identified and screened.

Komagataeibacter sucrofermentans

A literature search was performed in PubMed database, using the search term “Komagataeibacter sucrofermentans” from 2010*: 11 hits were identified, all concerning the cellulose production capacity.

*Keywords: “Acetobacter xylinus subsp. Sucofermentans” (seven hits), “Gluconacetobacter sucrofermentans” (nine hits, including those seven found with “Acetobacter xylinus subsp. Sucofermentans”), “Komagataibacter sucrofermentans” (two hits).

Another search was performed in Google: “Komagataeibacter sucrofermentans” and “taxonomy”: three references were found.
Appendix B – Protocol for Extensive literature search (ELS), relevance screening, and article evaluation for the maintenance and update of list of QPS-recommended biological agents (reply to ToR 2)

The following protocol for extensive literature search (ELS) will be used in the context of the EFSA self-task mandate on the list of QPS-recommended biological agents intentionally added to the food or feed (EFSA-Q-2016-00684).

B.1. Description of the process

An ELS of studies related to safety concerns for humans, animals, plants and/or the environment of microorganisms recommended for the Qualified Presumption of Safety (QPS) 2019 list will be performed.

The process will be performed according to the following main steps:

- ELS for potentially relevant citations;
- Relevance screening to select the citations identified by the literature search, based on titles and abstract and then full-text;
- Evaluation of articles according to pre-specified categories of possible safety concerns;
- Discussion between experts to come to collective expert evaluation of the outcome, reflected in the QPS Opinion and Panel Statements.

Considering the purpose of the QPS approach, a broad search will be performed. The review questions will be broken down into key elements using the PECO conceptual model:

- Population of interest (P);
- Exposure of interest (E);
- Comparator (C);
- Outcomes of interest (O).

B.1.1. Objective

The aim is to identify any publicly available studies reporting on safety concerns for humans, animals or the environment caused by microorganisms on the QPS recommended list (see Appendix E).

B.1.2. Target population

The populations of interest are humans, animals, plants and the environment.

B.1.3. Exposure

Citations must report on at least one species included in one of the five groups of named species specified in the EFSA QPS recommended list of the QPS 2016 update (see Table A1 in Appendix A to (EFSA BIOHAZ Panel, 2017a)):

a) Gram-positive non-spore-forming bacteria;

b) Gram-positive spore-forming bacteria;

c) Gram-negative bacteria;

b) Viruses used for plant protection;

e) Yeasts.

In more detail:

a) Gram-positive non-spore forming bacteria:

- *Bifidobacterium adolescentis*, *Bifidobacterium animalis*, *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium longum*, *Carnobacterium divergens*, *Corynebacterium glutamicum*, *Lactobacillus acidophilus*, *Lactobacillus amylyticus*, *Lactobacillus animalis*, *Lactobacillus amylovorus*, *Lactobacillus alimentarius*, *Lactobacillus aviaris*, *Lactobacillus brevis*, *Lactobacillus buchneri*, *Lactobacillus casei*,

- *Lactobacillus cellobiosus*, *Lactobacillus collinoides*, *Lactobacillus corniformis*, *Lactobacillus crispatus*,

- *Lactobacillus curvatus*, *Lactobacillus delbrueckii*, *Lactobacillus diolivorans* Lactobacillus farcininis,*

- *Lactobacillus fermentum*, *Lactobacillus gallinarum*, *Lactobacillus gasseri*, *Lactobacillus helveticus,*
Lactobacillus hilgardii, Lactobacillus johnsonii, Lactobacillus kefinofaciens, Lactobacillus kefir, Lactobacillus mucosae, Lactobacillus panis, Lactobacillus paracasei, Lactobacillus paraplantarum, Lactobacillus pentosus, Lactobacillus plantarum, Lactobacillus pontis, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus sakei, Lactobacillus salivarius, Lactobacillus sanfranciscensis, Lactococcus lactis, Leuconostoc citreum, Leuconostoc lactis, Leuconostoc mesenteroides, Leuconostoc pseudomesenteroides, Microbacterium imperiale, Oenococcus oeni, Pasteuria nishizawai, Pedicoccus acidilactici, Pedicoccus dextrinicus, Pedicoccus parvulus, Pedicoccus pentosaceus, Propionibacterium freudenreichii, Propionibacterium acidopropionici, Streptococcus thermophilus;

b) Gram-positive spore-forming bacteria:

Bacillus amylo liquafaciens, Bacillus atrophaeus, Bacillus clausii, Bacillus coagulans, Bacillus flexus, Bacillus fusiformis, Bacillus lentus, Bacillus licheniformis, Bacillus megaterium, Bacillus mojavensis, Bacillus pumilus, Bacillus smithii, Bacillus subtilis, Bacillus vallismortis, Geobacillus stearothermophilus;

c) Gram-negative bacteria:

Gluconobacter oxydans; Xanthomonas campestris

d) Viruses used for plant protection:

Plant viruses (Family): Alphaflexiviridae, Potyviridae
Insect viruses (Family): Baculoviridae

e) Yeasts:

Candida cylindracea, Debaryomyces hansenii, Hanseniaspora uvarum, Kluyveromyces lactis, Kluyveromyces marxianus, Komagataella pastoris, Lindnera jadinii, Ogataea angusta, Saccharomyces bayanus, Saccharomyces cerevisiae, Saccharomyces pastorianus, Schizosaccharomyces pombe, Wickerhamomyces anomalous, Xanthophyllomyces dendrorhous.

For the yeast species, as previously, the name of the teleomorphic form is used in the list of QPS species, when available. Important synonyms and older names were also included in the searches. For instance, names of the anamorphic growth forms were included, when such a form is known:

- Debaryomyces hansenii: anamorph Candida famata;
- Hanseniaspora uvarum: anamorph Kloeckera apiculata;
- Kluyveromyces lactis: anamorph Candida spherica;
- Kluyveromyces marxianus: anamorph Candida kefyr;
- Komagataella pastoris: synonym Pichia pastoris;
- Lindnera jadinii: synonyms Picha jadinii, Hansenula jadinii, Torulopsis utilis, anamorph Candida utilis;
- Ogataea angusta: synonym Picha angusta;
- Saccharomyces cerevisiae: synonym Saccharomyces bouardii;
- Saccharomyces pastorianus: synonym Saccharomyces carlsbergensis;
- Wickerhamomyces anomalous: synonyms Hansenula anomala, Picha anomala, Saccharomyces anomalous, anamorph Candida pelliculosa;
- Xanthophyllomyces dendrorhous: anamorph Phaffia rhodozyma.

B.1.4. Comparator

It is expected that the prevalent study designs will be case reports or case series and studies based on surveys or isolate collections. The remaining study designs may include: studies using laboratory isolates; randomised controlled trials, field trials, or experimental designs in the laboratory; experimental designs in live animals with a deliberate disease challenge; observational study designs; animal or insect models; investigations to identify or to understand the causes of safety concerns (e.g. identification, characterisation of toxic factors, virulence mechanisms); studies to demonstrate beneficial effects but with reporting of unwanted side-effects.

Since it is expected that in the majority of the study designs relevant for the review question, the comparator will not be available, the latter will not be included as a key element in the search strategy.
B.1.5. Outcomes of interest

The outcomes of interest to this ELS are:

Question 1:
- potential harms;
- safety issues;
- virulence or infectivity;
- intoxication.

Question 2:
- (acquired/intrinsic) antimicrobial resistance (AMR) covering phenotypic and genotypic aspects.

The QPS concept does not address hazards linked to the formulation or processing of the products based on biological agents added into the food or feed chain. Neither the safety of users handling the product nor the genetic modifications are taken into account.

B.1.6. Identification of the review questions

The following research questions will be addressed:

- Is there evidence of any safety concerns, including virulence features and toxin production, for humans, animals, plants and/or the environment associated with microbial species currently recommended for the QPS list since the previous QPS review (i.e. published from June 2016 until June 2019)?
- Is there evidence related to the presence or absence of antimicrobial resistance or antimicrobial resistance genes for the same microbial species published during the same time period?

B.2. Eligibility criteria for study selection

The selection of studies relevant to questions 1 and 2 will be performed applying the eligibility criteria described in Table B.1 below.

Table B.1: Eligibility criteria for questions 1 and 2

| Criteria                      | Details                                                                 |
|-------------------------------|-------------------------------------------------------------------------|
| Study design                  | No specific type of study design will be used to include/exclude relevant studies, although it is expected that the prevalent study designs will be case reports or case series and studies based on surveys or isolate collections |
| Study characteristics:        | No exclusion will be based on study characteristics                      |
| Population                    | Humans, animals, plants, environment                                      |
| Exposure                      | Studies must report on at least one TU as identified in Section B.1.3     |
| Outcome of interest           | Outcomes as listed in Section B.1.5                                       |
| Language                      | English                                                                  |
| Time                          | From June 2016 until end June 2019                                       |
| Publication type              | Primary research studies and secondary studies reporting previously unpublished primary studies |

B.3. Literature searches

Searches will be conducted in a range of relevant information sources to identify any evidence of safety concerns and AMR regarding the target microbial species.

Considering the results of the previous QPS exercise, to handle the high number of studies identified in each group, 20 search strategies were prepared: three for yeasts, one for insect viruses, one for plant viruses, 13 for Gram-positive bacteria and two for Gram-negative bacteria according to named species specified by EFSA in the QPS recommended list of the QPS 2016 update (see Table A1 in Appendix A to (EFSA BIOHAZ Panel, 2017a)).

The 20 subgroups of target microbial species will be searched separately.

Each search strategy will comprise two elements: the search terms (Section B.3.1) and the information sources (Section B.3.2) to be searched.
B.3.1.    Search terms

The search strategies used to identify studies are given in Appendix C. Each strategy will comprise two key elements:

- Target microbial species as described in Section B.1.3 (‘Exposure’);
- Safety issues as described in Section B.1.5 (‘Outcomes’).

In order to maximise the sensitivity of the search for the species for which the number of overall publications in the relevant time period is expected to be low, the search strategy will not include outcome-related terms.

The population of interest (humans, animals, plants or the environment) will not be included as a key element in the search strategies, as it is often not explicitly described within a title or abstract. It would also have been difficult to describe adequately such a broad population using title/abstract words and/or subject headings. Population information will be captured at the time of evaluating the articles (see Section B.1 above).

Search terms for safety issues were identified in close collaboration with the information specialist; example of such terms, are the following: ‘toxin*’, ‘disease*’, ‘infection*’, ‘clinical*’, ‘virulen*’, ‘antimicrobial resistant*’, ‘endocarditis’.

The 20 subgroups of target microbial species will be entered on separate search lines. The search line for each group will be combined with the safety terms individually.

The searches will not be limited by language or study design.

The review period will be from June 2016 to June 2019.

B.3.2.    Information sources searched

The same information sources used for the previous QPS exercise (EFSA BIOHAZ Panel, 2017a) will be searched for studies reporting safety concerns regarding the target microbial species (see Table B.2 below).

Table B.2: Information sources to be searched to identify relevant studies

| Information source                           | Interface                                      |
|---------------------------------------------|------------------------------------------------|
| Web of Science Core Collection              | Web of Science, Thomson Reuters 2018           |
| CAB Abstracts                               | Web of Science, Thomson Reuters 2018           |
| BIOSIS Citation Index                       | Web of Science, Thomson Reuters 2018           |
| MEDLINE                                     | Web of Science, Thomson Reuters 2018           |
| Food Science Technology Abstracts (FSTA)    | Web of Science, Thomson Reuters 2018           |

Search results will be downloaded from the information sources and imported into EndNote® X8 bibliographic management software. For each of the 20 species groups, within-group removal of duplicate entries will be done in EndNote® X8. Following uploading of the species groups into the DistillerSR online software, removal of duplicates will again be undertaken, using the Duplicate Detection feature.

B.4.    Study selection and article evaluation

To identify potentially relevant studies to be included in the review the studies will be selected by a three-step procedure using the DistillerSR online software.

The results of the different phases of the study selection process will be reported in a flowchart as recommended in the PRISMA statement on preferred reporting items for systematic reviews and meta-analyses (Moher et al., 2009).

B.4.1.    Screening for potential relevance at title level

Articles will initially be screened at title level in parallel by two Working Group (WG) expert reviewers and, if needed, EFSA staff.

---

10 DistillerSR, Evidence Partners, Ottawa, Canada. https://www.evidencepartners.com/products/distillersr-systematic-review-software/
If the information in the title is not relevant for the research objectives, the article will not proceed to the next step (Section B.4.2).

Articles that will be excluded during screening at this step will be stored in Distiller SR.

In case of doubts or divergences between the reviewers, the paper will proceed to step 2.

B.4.2. Screening for potential relevance at title and abstract level

The articles passing the first step will undergo a screening at abstract level in parallel by two experts.

If the information in title and abstract is not relevant for the research objectives, the article will not proceed to the next step (Section B.4.3).

Articles that will be excluded during screening at this step will be stored in Distiller SR.

In case of doubts or divergences between the reviewers, the paper will proceed to step 3.

B.4.3. Article evaluation

The aim of this step will be to confirm that the article is relevant for the QPS project and, in case it is, to evaluate it. It will be carried out at full text level.

The articles passing the second step will undergo a validation procedure carried out by two experts. One reviewer will initially be tasked with the evaluation of a paper. The evaluation will be then forwarded to another reviewer for the validation of the appraisal received.

In case of disagreement with the initial appraisal, the second reviewer will write down their comments. The reviewers will initially try to solve the disagreement. In case this will not be possible, the conflicting information will be presented for collective expert evaluation of the ELS outcome (see Section B.5).

If the information contained in the article is not relevant for the research objectives, the article will not be evaluated. Articles that will not be considered relevant will be stored in Distiller SR.

B.4.3.1. Questions for study selection and article evaluation

STEP 1 (Screening for potential relevance):

**Question 1**: Is the full-text available, in English and dealing with safety concerns?
- Yes: Include and continue to Article evaluation form;
- Full text not available: Exclude;
- Full text not in English: Exclude;
- Full text in English but not dealing with safety concerns: Exclude.

STEP 2 (Article evaluation):

**Question 2**: Identification of the microorganisms
- The article will be characterised in terms of the microorganisms involved
  Single choice question: the Experts will identify the microorganism/s described in the article. In case more than one microorganism is described in the paper, the form will be repeated for each microorganism.

**Question 3**: Is there any "methodological" problem identified in the paper under consideration?
- No problems identified;
- Yes some problems were identified.

**Question 4**: Which "methodological" problems were identified in the paper under consideration? (this question will appear in case in question 3 the option “Yes some problems were identified” will be selected)
- Methodology used for identity confirmation of the microorganism;
- Reliability of the source attribution;
- Misuse of the microorganism (e.g. parenteral exposure);
- Predisposing factors in the exposed subjects;
- Others.
When one of the above options will be selected a dedicated free text box will appear to describe the problem identified.

*Question 5: Is there any safety concern identified?* (this question will appear in case in question 3 the option “No problems identified” will be selected)

- No safety concerns identified;
- Yes some safety concerns were identified.

*Question 6: Which safety concerns were identified?* (this question will appear in case in question 5 the option “Yes some safety concerns were identified” will be selected)

- On human health;
- On animal health;
- On the environment;
- On AMR;
- On other aspects.

When one of the above options will be selected a dedicated free text box will appear to describe the safety concern identified.

*Question 7: Overall, is there any information that could potentially lead to a change in the QPS status of the microorganism?* (this question will appear in case in question 5 the option “Yes some safety concerns were identified” will be selected)

- No;
- Yes.

In case the option “Yes” will be selected a dedicated free text box will appear to describe the information that could potentially lead to a change in the QPS status of the microorganism.

**B.5. Collective expert evaluation of the ELS outcome and presentation in the QPS opinion**

The overall results of the searches and evaluations of individual articles will be presented in tabular format for each group/sub-group and species. These results will be further evaluated collectively by the working group and the outcome will be reflected in the QPS opinion.

**B.6. Update of the process**

The literature search, study selection and collective expert evaluation will be repeated every 6 months.

**References**

EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards), 2017. Scientific Opinion on the update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA. EFSA Journal 2017;15 (1):4664, 177 pp. https://doi.org/10.2903/j.efsa.2017.4664

Moher D, Liberati A, Tetzlaff J, Altman DG and the PRISMA Group, 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, e1000097.
Appendix C – Search strategies for the maintenance and update of list of QPS-recommended biological agents (reply to ToR 2)

Gram-Positive Non-Spore-forming Bacteria

*Bifidobacterium* spp.

| String for species                                                                 | String                                                                 |
|-----------------------------------------------------------------------------------|------------------------------------------------------------------------|
| “Bifidobacterium adolescentis” OR “Bifidobacterium animalis” OR “Bifidobacterium bifidum” OR “Bifidobacterium breve” OR “Bifidobacterium longum” OR “B. adolescentis” OR “B. animalis” OR “B. bifidum” OR “B. breve” OR “B. longum” |                                                                          |

**OUTCOME**

1. Antimicrobial/Antibiotic/Antimycotic
   - infection* OR abscess* OR sepsis* OR septic* OR bacteremia OR bacteraemia OR toxin*

2. Infection/Bacteremia/Fungemia/Sepsis
   - endocarditis OR abscess OR meningitis

3. Type of disease
   - opportunistic OR virulent*

4. Mortality/Morbidity
   - clinical* OR death* OR morbidity* OR mortality* OR disease* OR illness*

5. Disease Risk
   - Not applied

*Carnobacterium divergens*

| String for species                                                                 | String       |
|-----------------------------------------------------------------------------------|--------------|
| “Carnobacterium divergens” OR “C divergens”                                       |              |

**OUTCOME**

6. Antimicrobial/Antibiotic/Antimycotic
   - Not applied

7. Infection/Bacteremia/Fungemia/Sepsis
   - Not applied

8. Type of disease
   - Not applied

9. Mortality/Morbidity
   - Not applied

10. Disease Risk
    - Not applied

*Corynebacterium glutamicum*

| String for species                                                                 | String                                                                 |
|-----------------------------------------------------------------------------------|------------------------------------------------------------------------|
| “Corynebacterium glutamicum” OR “C glutamicum” OR “Brevibacterium lactofermentum” OR “B lactofermentum” |                                                                          |

**OUTCOME**

1. Antimicrobial/Antibiotic/Antimycotic
   - “antimicrobial resistant” OR “antibiotic resistant” OR “antimicrobial susceptible”

2. Infection/Bacteremia/Fungemia/Sepsis
   - infection* OR abscess* OR sepsis* OR septic* OR bacteremia OR bacteraemia OR toxin*

3. Type of disease
   - Not applied

4. Mortality/Morbidity
   - clinical* OR death* OR morbidity* OR mortality* OR disease* OR illness*

5. Disease Risk
   - opportunistic OR virulent*
### Lactobacillus spp.

#### String for species

```
"Lactobacillus acidophilus" OR "Lactobacillus amylolyticus" OR "Lactobacillus amylovorus" OR "Lactobacillus alimentarius" OR "Lactobacillus animalis" OR "Lactobacillus aviarum" OR "Lactobacillus brevis" OR "Lactobacillus buchneri" OR "Lactobacillus casei" OR "Lactobacillus zeae" OR "Lactobacillus cellobiosus" OR "Lactobacillus coryniformis" OR "Lactobacillus crispatus" OR "Lactobacillus curvatus" OR "Lactobacillus delbrueckii" OR "Lactobacillus diolivorans" OR "Lactobacillus farciminis" OR "Lactobacillus fermentum" OR "Lactobacillus gallinarum" OR "Lactobacillus gaseri" OR "Lactobacillus helveticus" OR "Lactobacillus hilgardii" OR "Lactobacillus johnsonii" OR "Lactobacillus kefir" OR "Lactobacillus kefirii" OR "Lactobacillus mucosae" OR "Lactobacillus panis" OR "Lactobacillus collinoides" OR "Lactobacillus paracasei" OR "Lactobacillus paraplantarum" OR "Lactobacillus pentosus" OR "Lactobacillus plantarum" OR "Lactobacillus pontis" OR "Lactobacillus reuteri" OR "Lactobacillus rhamnosus" OR "Lactobacillus sakei" OR "Lactobacillus salivarius" OR "Lactobacillus sanfranciscensis" OR "L acidophilus" OR "L amylovorus" OR "L alimentarius" OR "L animalis" OR "L avianes" OR "L brevis" OR "L buchneri" OR "L casei" OR "L zeae" OR "L cellobiosus" OR "L coryniformis" OR "L curvatus" OR "L delbrueckii" OR "L diolivorans" OR "L farriminis" OR "L fermentum" OR "L gallinarum" OR "L gaseri" OR "L helveticus" OR "L hilgardii" OR "L johnsonii" OR "L kefir" OR "L kefirii" OR "L mucosae" OR "L panis" OR "L collinoides" OR "L paracasei" OR "L paraplantarum" OR "L pentosus" OR "L plantarum" OR "L pontis" OR "L reuteri" OR "L rhamnosus" OR "L sakei" OR "L salivarius" OR "L sanfranciscensis"
```

| OUTCOME                | String                                      |
|------------------------|---------------------------------------------|
| 1. Antimicrobial/Antibiotic/Antimycotic | "antimicrobial resistant**" OR "antibiotic resistant**" OR "antimicrobial susceptibil**" |
| 2. Infection/Bacteremia/Fungemia/Sepsis    | infection* OR abscess* OR sepsis* OR septic* OR bacteremia OR bacteraemia OR toxin* |
| 3. Type of disease          | endocarditis OR abscess OR meningitis       |
| 4. Mortality/Morbidity     | Not applied                                 |
| 5. Disease Risk            | opportunistic OR virulen*                   |

### Lactococcus lactis

#### String for species

```
"Lactococcus lactis" OR "L lactis"
```

| OUTCOME                | String                                      |
|------------------------|---------------------------------------------|
| 1. Antimicrobial/Antibiotic/Antimycotic | "antimicrobial resistant**" OR "antibiotic resistant**" OR "antimicrobial susceptibil**" |
| 2. Infection/Bacteremia/Fungemia/Sepsis    | infection* OR abscess* OR sepsis* OR septic* OR bacteremia OR bacteraemia OR toxin* |
| 3. Type of disease          | endocarditis OR abscess OR meningitis       |
| 4. Mortality/Morbidity     | clinical* OR death* OR morbidity* OR mortality OR disease* OR illness* |
| 5. Disease Risk            | opportunistic OR virulen*                   |
### Leuconostoc spp.

**String for species**

"Leuconostoc mesenteroides" OR "Leuconostoc lactis" OR "Leuconostoc pseudomesenteroides" OR "Leuconostoc citreum" OR "L mesenteroides" OR "L lactis" OR "L pseudomesenteroides" OR "L citreum"

| OUTCOME | String |
|---------|--------|
| 1. Antimicrobial/Antibiotic/Antimycotic | "antimicrobial resistant" OR "antibiotic resistant" OR "antimicrobial susceptible" |
| 2. Infection/Bacteremia/Fungemia/Sepsis | infection OR abscess OR sepsis OR septic OR bacteraemia OR bacteraemia OR toxin |
| 3. Type of disease | Not applied |
| 4. Mortality/Morbidity | clinical OR death OR morbid OR mortal OR disease OR illness |
| 5. Disease Risk | opportunistic OR virulent |

### Microbacterium imperiale

**String for species**

"Microbacterium imperiale" OR "M imperiale"

| OUTCOME | String |
|---------|--------|
| 6. Antimicrobial/Antibiotic/Antimycotic | Not applied |
| 7. Infection/Bacteremia/Fungemia/Sepsis | Not applied |
| 8. Type of disease | Not applied |
| 9. Mortality/Morbidity | Not applied |
| 10. Disease Risk | Not applied |

### Oenococcus spp.

**String for species**

"Oenococcus oeni" OR "O oeni"

| OUTCOME | String |
|---------|--------|
| 11. Antimicrobial/Antibiotic/Antimycotic | Not applied |
| 12. Infection/Bacteremia/Fungemia/Sepsis | Not applied |
| 13. Type of disease | Not applied |
| 14. Mortality/Morbidity | Not applied |
| 15. Disease Risk | Not applied |

### Pasteuria nishizawae

**String for species**

"Pasteuria nishizawae" OR "P nishizawae"

| OUTCOME | String |
|---------|--------|
| 16. Antimicrobial/Antibiotic/Antimycotic | Not applied |
| 17. Infection/Bacteremia/Fungemia/Sepsis | Not applied |
| 18. Type of disease | Not applied |
| 19. Mortality/Morbidity | Not applied |
| 20. Disease Risk | Not applied |
### Pediococcus spp.

**String for species**

"Pediococcus pentosaceus" OR "Pediococcus dextrinicus" OR "Pediococcus acidilactici" OR "Pediococcus parvulus" OR "P pentosaceus" OR "P dextrinicus" OR "P acidilactici" OR "P parvulus"

| OUTCOME                          | String                     |
|---------------------------------|----------------------------|
| 1. Antimicrobial/Antibiotic/Antimycotic | Not applied               |
| 2. Infection/Bacteremia/Fungemia/Sepsis     | Not applied               |
| 3. Type of disease               | Not applied               |
| 4. Mortality/Morbidity           | Not applied               |
| 5. Disease Risk                  | Not applied               |

### Propionibacterium spp.

**String for species**

"Propionibacterium acidipropionici" OR "Propionibacterium freudenreichii" OR "P acidipropionici" OR "P freudenreichii"

| OUTCOME                          | String                     |
|---------------------------------|----------------------------|
| 1. Antimicrobial/Antibiotic/Antimycotic | Not applied               |
| 2. Infection/Bacteremia/Fungemia/Sepsis     | Not applied               |
| 3. Type of disease               | Not applied               |
| 4. Mortality/Morbidity           | Not applied               |
| 5. Disease Risk                  | Not applied               |

**Number papers retrieved and notes**

176 papers retrieved

### Streptococcus thermophilus

**String for species**

"Streptococcus thermophilus" OR "S thermophilus" OR "Streptococcus thermophilus" OR "S thermophilus"

| OUTCOME                          | String                     |
|---------------------------------|----------------------------|
| 1. Antimicrobial/Antibiotic/Antimycotic | "antimicrobial resistant" OR "antibiotic resistant" OR "antimicrobial susceptibility" |
| 2. Infection/Bacteremia/Fungemia/Sepsis     | infection* OR abscess* OR sepsis* OR septic* OR bacteremia OR bacteraemia OR toxin* |
| 3. Type of disease               | Clinical* OR death* OR morbid* OR mortality* OR disease* OR illness* |
| 4. Mortality/Morbidity           | opportunistic OR virulent*|
| 5. Disease Risk                  | Not applied               |
Gram-Positive Spore-forming Bacteria

*Bacillus* spp.

### String for species

"Bacillus amyloliquefaciens" OR "Bacillus coagulans" OR "Bacillus clausii" OR "Bacillus atrophaeus" OR "Bacillus flexus" OR "Bacillus fusiformis" OR "Lysinibacillus fusiformis" OR "Bacillus licheniformis" OR "Bacillus lentus" OR "Bacillus mojavensis" OR "Bacillus megaterium" OR "Bacillus vallismortis" OR "Bacillus smithii" OR "Bacillus subtilis" OR "Bacillus pumilus" OR "Geobacillus stearothermophilus" OR "B amyloliquefaciens" OR "B coagulans" OR "B clausii" OR "B atrophaeus" OR "B flexus" OR "B fusiformis" OR "L fusiformis" OR "B licheniformis" OR "B lentus" OR "B mojavensis" OR "B megaterium" OR "B vallismortis" OR "B smithii" OR "B subtilis" OR "B pumilus" OR "G stearothermophilus"

### OUTCOME

1. Antimicrobial/Antibiotic/Antimycotic
2. Infection/Bacteremia/Fungemia/Sepsis
3. Type of disease
4. Mortality/Morbidity
5. Disease Risk

### String

"antimicrobial resistan*" OR "antibiotic resistan*" OR "antimicrobial susceptibil*

Infection* OR abscess* OR sepsis* or septic* OR bacteremia OR bacteraemia OR toxin*

endocarditis OR abscess OR meningitis

Not applied

opportunistic OR virulen*

Gram-negative bacteria

*Gluconobacter oxydans*

### String for species

"Gluconobacter oxydans" OR "G oxydans"

### OUTCOME

1. Antimicrobial/Antibiotic/Antimycotic
2. Infection/Bacteremia/Fungemia/Sepsis
3. Type of disease
4. Mortality/Morbidity
5. Disease Risk

### String

Not applied

Not applied

Not applied

Not applied

Not applied

*Xanthomonas campestris*

### String for species

"Xanthomonas campestris" OR "X campestris"

### OUTCOME

1. Antimicrobial/Antibiotic/Antimycotic
2. Infection/Bacteremia/Fungemia/Sepsis
3. Type of disease
4. Mortality/Morbidity
5. Disease Risk

### String

Not applied

Not applied

Not applied

Not applied

Not applied
### Yeasts

**TUs without keywords for OUTCOME**

| String for species | |
|--------------------|-------------------|
| “Candida cylindracea” OR “Debaryomyces Hansenii” OR “Candida famata” OR “Hanseniaspora uvarum” OR “Kloeckera apiculata” OR “Ogataea angusta” OR “Pichia angusta” OR “Saccharomyces bayanus” OR “Saccharomyces pastorianus” OR “Saccharomyces carlsbergensis” OR “Wickerhamomyces anomalus” OR “Hansenula anomala” OR “Pichia anomala” OR “Saccharomyces anomalus” OR “Candida pelliculosa” OR “Xanthophyllomyces dendrorhous” OR “Pichia rhodozyma” OR “C cylindracea” OR “D hansenii” OR “C famata” OR “H uvarum” OR “K apiculata” OR “O angusta” OR “P angusta” OR “S bayanus” OR “S pastorianus” OR “S carlsbergensis” OR “W anomalous” OR “H anomala” OR “P anomala” OR “S anomalous” OR “C pelliculosa” OR “X dendrorhous” OR “P rhodozyma” |

### OUTCOME

| String | |
|--------|-------------------|
| 1. Antimicrobial/Antibiotic/Antimycotic | Not applied |
| 2. Infection/Bacteremia/Fungemia/Sepsis | Not applied |
| 3. Type of disease | Not applied |
| 4. Mortality/Morbidity | Not applied |
| 5. Disease Risk | Not applied |

**TUs with keywords for OUTCOME except for type of disease and morbility/mortality**

| String for species | |
|--------------------|-------------------|
| “Kluyveromyces lactis” OR “Candida spherica” OR “Kluyveromyces marxianus” OR “Candida kefyr” OR “Komagataea pastoris” OR “Pichia pastoris” OR “Lindnera jadinii” OR “Pichia jadinii” OR “Hansenula jadinii” OR “Torulopsis utilis” OR “Candida utilis” OR “Schizosaccharomyces pombe” OR “K lactis” OR “C spherica” OR “K marxianus” OR “C kefyr” OR “K pastoris” OR “P pastoris” OR “L jadinii” OR “P jadinii” OR “H jadinii” OR “T utilis” OR “C utilis” OR “S pombe” |

### OUTCOME

| String | |
|--------|-------------------|
| 1. Antimicrobial/Antibiotic/Antimycotic | “antimicrobial resistant*” OR “antimycotic resistant*” OR “antimicrobial susceptibl***” |
| 2. Infection/Bacteremia/Fungemia/Sepsis | “infection* OR abscess* OR sepsis* or septic* OR fungemia OR fungaemia OR mycos*” |
| 3. Type of disease | Not applied |
| 4. Mortality/Morbidity | Not applied |
| 5. Disease Risk | opportunistic OR virulen* |
### TUs with keywords for OUTCOME except for type of disease

**String for species**

"saccharomyces cerevisiae" OR "saccharomyces boulardii" OR "s cerevisiae" OR "s boulardii"

**OUTCOME**

1. Antimicrobial/Antibiotic/Antimycotic
   - "antimicrobial resistant" OR "antimycotic resistant" OR "antimicrobial susceptible"
2. Infection/Bacteremia/Fungemia/Sepsis
   - infection* OR abscess* OR sepsis* or septic* OR fungemia OR fungaemia OR mycos*
3. Type of disease
   - Not applied
4. Mortality/Morbidity
   - clinical* OR death* OR morbidit* OR mortalit* OR disease* OR illness*
5. Disease Risk
   - opportunistic OR virulent*

### Viruses used for plant protection

**Alphaflexiviridae**

**String for species**

Alphaflexiviridae OR Potyviridae

**OUTCOME**

1. Antimicrobial/Antibiotic/Antimycotic
   - Not applied
2. Infection/Bacteremia/Fungemia/Sepsis
   - necros*
3. Type of disease
   - Not applied
4. Mortality/Morbidity
   - mortalit* OR "safety concern" OR "health hazard"
5. Disease Risk
   - virulent*

**Baculoviridae**

**String for species**

"nuclear polyhedrosis virus" OR granulovirus OR baculoviridae

**OUTCOME**

1. Antimicrobial/Antibiotic/Antimycotic
   - Not applied
2. Infection/Bacteremia/Fungemia/Sepsis
   - Not applied
3. Type of disease
   - "nuclear polyhedrosis" OR granulosis
4. Mortality/Morbidity
   - mortalit* OR "safety concern" OR "health hazard"
5. Disease Risk
   - Not applied
Appendix D – References selected from the ELS exercise as relevant for the QPS for searches from January to June 2018 (reply to ToR 2)

Gram-Positive Non-Sporulating Bacteria

**Bifidobacterium spp.**

Martinez N, Luque R, Milani C, Ventura M, Banuelos O and Margolles A, 2018. A gene homologous to rRNA methylase genes confers erythromycin and clindamycin resistance in *Bifidobacterium breve*. Applied and Environmental Microbiology, 84.

Kim MJ, Ku S, Kim SY, Lee HH, Jin H, Kang S, Li R, Johnston TV, Park MS and Ji GE, 2018. Safety Evaluations of *Bifidobacterium bifidum* BGN4 and *Bifidobacterium longum* BORI. International Journal of Molecular Sciences, 19.

Kumar K, Saadi M, Ramsey FV, Schey R and Parkman HP, 2018. Effect of *Bifidobacterium infantis* 35624 (Align) on the lactulose breath test for small intestinal bacterial overgrowth. Digestive Diseases and Sciences, 63, 989-995.

Simpson MR, Avershina E, Storro O, Johnsen R, Rudi K and Oien T, 2018. Breastfeeding-associated microbiota in human milk following supplementation with *Lactobacillus rhamnosus* GG, *Lactobacillus acidophilus* La-5, and *Bifidobacterium animalis* ssp. lactis Bb-12. Journal of Dairy Science, 101, 889-899.

**Carnobacterium divergens**

None.

**Corynebacterium glutamicum**

None.

**Lactobacilli spp.**

de Seynes C, Dutronc H, Cremer P and Dupon M, 2018. *Lactobacillus casei* prosthetic joint infection. Medecine et Maladies Infectieuses.

Biesiada G, Krycinska R, Czepiel J, Stazyk K, Kedzierska J and Garlicki A, 2018. Meningoencephalitis caused by *Lactobacillus plantarum* - case report. The International Journal of Neuroscience, 1-9.

Boumis E, Capone A, Galati V, Venditti C and Petrosillo N, 2018. Probiotics and infective endocarditis in patients with hereditary hemorrhagic telangiectasia: a clinical case and a review of the literature. BMC Infectious Diseases, 18.

Harding-Theobald E and Maraj B, 2018. Spontaneous Bacterial Peritonitis due to *Lactobacillus paracasei* in Cirrhosis. Case Reports in Gastrointestinal Medicine.

Garcia Carretero R, Regodon Dominguez M, Ruiz Bastian M and Lopez Lomba M, 2018. *Lactobacillus salivarius* infection as a postoperative complication after bariatric surgery. Enfermedades Infecciosas Y Microbiologia Clinica, 36, 60-61.

Kane AF, Bhatia AD, Denning PW, Shane AL and Patel RM, 2018. Routine Supplementation of *Lactobacillus rhamnosus* GG and Risk of Necrotizing Enterocolitis in Very Low Birth Weight Infants. Journal of Pediatrics, 195, 73-77.

Koyama S, Fujita H, Shimosato T, Kamijo A, Ishiyama Y, Yamamoto E, Ishii Y, Hattori Y, Hagiwara M, Yamazaki E, Tomita N, Nakajima H and Yokohama Cooperative Study Group for, Hematology, 2018. Septicemia from *Lactobacillus rhamnosus* GG, from a Probiotic Enriched Yogurt, in a Patient with Autologous Stem Cell Transplantation. Probiotics and Antimicrobial Proteins.

**Lactococcus lactis**

Georgountzos G, Michopoulos C, Grivokostopoulos C, Kolosaka M, Vlassopoulou N and Lekkou A, 2018. Infective endocarditis in a young adult due to *Lactococcus lactis*: a case report and review of the literature. Case Reports in Medicine.

Wunnemann H, Eskens U, Prenger-Berninghoff E, Ewers C and Lierz M, 2018. *Lactococcus lactis*, causative agent of an endocarditis valvaris and parietalis thromboticans in the allis shad, *Alosa alosa* (L.). Journal of Fish Diseases.

Mussano F, Ferrocino I, GavriloVA N, Genova T, Dell’Acqua A, Cocolin L and Carossa S, 2018. Apical periodontitis: preliminary assessment of microbiota by 16S rRNA high throughput amplicon target sequencing. BMC Oral Health, 18.
Tato Rodriguez R, Guzman Figueroa DM, Trigo Daporta M and Garcia Campello M, 2018. Fever in an 80-year-old male carrying biologic aortic prosthesis endocarditis due to *Lactococcus lactis* subsp *lactis*. Journal of Clinical Microbiology, 56.

**Leuconostoc** spp.
Mussano F, Ferrocino I, Gavrilova N, Genova T, Dell’Acqua A, Cocolin L and Carossa S, 2018. Apical periodontitis: preliminary assessment of microbiota by 16S rRNA high throughput amplicon target sequencing. BMC Oral Health, 18.

Vahabzadeh S and Ozpinar H, 2018. Investigation of some biochemical properties, antimicrobial activity and antibiotic resistances of kefir supernatants and *Lactococcus lactis* ssp. *lactis* Strains isolated from raw cow milk and cheese samples. Kafkas Universitesi Veteriner Fakultesi Dergisi, 24, 443–450.

Lin X, Jiang Q, Liu J, Zhao F and Chen W, 2018. *Leuconostoc pseudomesenteroides*-associated hemophagocytic syndrome: a case report. Experimental and Therapeutic Medicine, 15, 1199–1202.

**Microbacterium imperiale**
None.

**Oenococcus oeni**
None.

**Pasteuria nishizawai**
None.

**Pediococcus** spp.
None.

**Propionibacterium** spp.
None.

**Streptococcus thermophilus**
None.

**Gram-Positive Spore-forming Bacteria**

**Bacillus** spp.
Kim MK, Yoon HY, Lee MH and Kim JH, 2018. Canine pyometra associated with *Bacillus* species: a case report. Veterinarni Medicina, 63, 143–149.

Tran TT, Varghese M and Baer S, 2018. Polymicrobial endocarditis caused by abiotrophia defectiva, *Bacillus cereus*, *Bacillus subtilis* and *Bacillus megaterium* in the setting of injection drug use. Journal of Investigative Medicine, 66, 473–473.

**Geobacillus stearothermophilus**
None.

**Gram-negative bacteria**

**Gluconobacter oxydans**
None.

**Xanthomonas campestris**
Sundin GW and Wang N, 2018. Antibiotic Resistance in Plant-Pathogenic Bacteria. Annual Review of Phytopathology.

**Yeasts**¹¹
Aslani N, Janbabaei G, Abastabar M, Meis JF, Babaeian M, Khodavaisy S, Boekhout T and Badali H, 2018. Identification of uncommon oral yeasts from cancer patients by MALDI-TOF mass spectrometry. BMC Infectious Diseases, 18.

¹¹ See also Table D.1.
Al-Tekreeti ARA, Al-Halbosiy MMF, Dheeb BL, Hashim AJ, Al-Zuhairi AFH and Mohammad FI, 2018. Molecular identification of clinical Candida isolates by simple and randomly amplified polymorphic DNA-PCR. Arabian Journal for Science and Engineering, 43, 163–170.

Charsizadeh A, Mirhendi H, Nikmanesh B, Eshghii H, Rahmani M, Farhang A, Bakhshi H and Makimura K, 2018. Candidemia in Children Caused by Uncommon Species of Candida. Archives of Pediatric Infectious Diseases, 6.

Dangarembizri R, Erlwanger KH, Rummel C, Roth, J, Madziva MT and Harden LM, 2018. Brewer’s yeast is a potent inducer of fever, sickness behavior and inflammation within the brain. Brain Behavior and Immunity, 68, 211–223.

Charsizadeh A, Nikmanesh B, Ahmadi B, Jalalizand N, Jafari Z, Rahmani M, Kordbacheh P and Mirhendi H, 2018. Frequency of Candida Species Isolated from Patients in Children’s Medical Center, Tehran, Iran. Archives of Pediatric Infectious Diseases, 6.

Charsizadeh A, Mirhendi H, Nikmanesh B, Eshghii H and Makimura K, 2018. Microbial epidemiology of candidaemia in neonatal and paediatric intensive care units at the Children’s Medical Center, Tehran. Mycoses, 61, 22–29.

Denis B, Chopin D, Piron P, Resche-Rigon M, Bretegade S, Gits-Muselli M, Peraldi M-N, Abboud I and Molina J-M, 2018. Candiduria in kidney transplant recipients: Is antifungal therapy useful? Mycoses, 61, 298–304.

Gaisne R, Jeddi F, Morio F, Le Clerc Q-C, Hourmant M, Blancho G, Giral M, Cantarovich D, Dental J and Ville S, 2018. Candida utilis fungaemia following endoscopic intervention on ureteral stent in a kidney transplant recipient: Case report and a review of the literature. Mycoses.

Jahanshiri Z, Manifar S, Moosa H, Asghari-Paskiabi F, Mahmoodzadeh H, Shams-Ghahfarokhi M and Razzaghi-Abayaneh M, 2018. Oropharyngeal candidiasis in head and neck cancer patients in Iran: Species identification, antifungal susceptibility and pathogenic characterization. Journal de Mycologie Medicale, 28, 361–366.

Kumar S, Dey S, Sena A, Kumar D and Akhter K, 2018. Characterization and antifungal susceptibility testing of Candida species isolated from clinical samples of patients attending Kathiar Medical College, Kathiar. BJHAR Journal of Evolution of Medical and Dental Sciences-Jemds, 7, 662–666.

Li M-C, Chang TC, Chen H-M, Wu C-J, Su S-L, Lee SSJ, Chen P-L, Lee N-Y, Lee C-C, Li C-W, Syue L-S and Ko W-C, 2018. Oligonucleotide Array and VITEK Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry in Species Identification of Blood Yeast Isolates. Frontiers in Microbiology, 9.

Ortiz B, Perez-Aleman E, Galo C and Fontecha G, 2018. Molecular identification of Candida species from urinary infections in Honduras. Revista Iberoamericana De Micologia, 35, 73–77.

Mount H, Revie NM, Todd RT, Anstett K, Collins C, Costanzo M, Boone C, Robbins N, Selmecki A and Cowen LE, 2018. Global analysis of genetic circuitry and adaptive mechanisms enabling resistance to the azole antifungal drugs. Plos Genetics, 14.

Musatti A, Mapelli C, Rollini M, Foschino R, Piccozi C, 2018. Can Zymomonas mobilis Substitute Saccharomyces cerevisiae in Cereal Dough Leavening? Foods, 7.

Mohamed, Nurul Aamawati, Pathmanathan, Siva Gowri, Hussin, Hazilawati, Zaini, Adilah inahtul Bushro, 2018. Distribution and Antifungal Susceptibility Pattern of Candida species at a Tertiary Hospital in Malaysia. Journal of Infection in Developing Countries, 12(2), 102-108.

Nejat, Ziba Abbasi, Farahyar, Shirin, Falahati, Mehraban, Khozani, Shahid Ashraf, Hosseini, Aga Fatemeh, Faizy, Azamsadat, Ekhtiar, Masoomne, Hashemi-Hafshenjan, Saeideh, 2018. Molecular Identification and Antifungal Susceptibility Pattern of Non-albicans Candida Species Isolated from Vulvovaginal Candidiasis. Iranian Biomedical Journal, 22(1), 33-41.

Mixao, Veronica, Gabaldon, Toni, 2018. Hybridization and emergence of virulence in opportunistic human yeast pathogens: Yeast, 35(1), 5-20.

Robledo-Leal, E., Rivera-Morales, L. G., Sangorrin, M. P., Gonzalez, G. M., Ramos-Alfano, G., Adame-Rodriguez, J. M., Alcocer-Gonzalez, J. M., Arechiga-Carvajal, E. T., Rodriguez-Padilla, C. (2018). Identification and susceptibility of clinical isolates of Candida spp. to killer toxins. Brazilian journal of biology = Revista brasileira de biologia, 78(4), 742-749.

Rajkowska K and Kunicka-Styczynska A, 2018. Typing and virulence factors of food-borne Candida spp. isolates. International Journal of Food Microbiology, 279, 57–63.

Rosenberg A, Ene IV, Bibi M, Zakin S, Segal ES, Ziv N, Dahan AM, Colombo AL, Bennett RJ and Berman J, 2018. Antifungal tolerance effect is distinct from resistance and is associated with persistent candidemia. Nature Communications, 9.

Scapaticci M, Bartolini A, Del Chierico F, Accardi C, Di Girolamo F, Masotti A, Muraca M and Putignani L, 2018. Phenotypic typing and epidemiological survey of antifungal resistance of Candida species detected in clinical samples of Italian patients in a 17 months’ period. Germs, 8, 58–66.

Salvatore S, Baris A, Turan D, Altunbas R and Sen S, 2018. The frequency, antifungal susceptibility and enzymatic profiles of Candida species in cases of onychomycosis infection. Microbial Pathogenesis, 116, 257–262.

Phadke SS, Maclean CJ, Zhao SY, Mueller EA, Michelotti LA, Norman KL, Kumar A and James TY, 2018. Genome-Wide Screen for Saccharomyces cerevisiae Genes Contributing to Opportunistic Pathogenicity in an Invertebrate Model Host. G3-Genes Genomes Genetics, 8, 63–78.

Scott LH, Mathews JC, Flematti GR, Filipovska A and Rackham O, 2018. An artificial yeast genetic circuit enables deep mutational scanning of an antimicrobial resistance protein. ACS Synthetic Biology.
Suwunnakorn S, Wakabayashi H, Kordalewska M, Perlin DS and Rustchenko E, 2018. FKS2 and FKS3 Genes of Opportunistic Human Pathogen Candida albicans Influence Echinocandin Susceptibility. Antimicrobial Agents and Chemotherapy, 62.

Siavoshi F, Sahraeem E, Ebrahimi H, Sarrafnejad A and Saniee P, 2018. Natural fruits, flowers, honey, and honeybees harbor Helicobacter pylori-positive yeasts. Helicobacter, 23.

Steenkamp ET, Wingfield MJ, McTaggart AR and Wingfield BD, 2018. Fungal species and their boundaries matter - Definitions, mechanisms and practical implications. Fungal Biology Reviews, 32, 104–116.

Sivamaruthi BS, 2018. A comprehensive review on clinical outcome of probiotic and synbiotic therapy for inflammatory bowel diseases. Asian Pacific Journal of Tropical Biomedicine, 8, 179–186.

Sekyere JO and Asante J, 2018. Emerging mechanisms of antimicrobial resistance in bacteria and fungi: advances in the era of genomics. Future Microbiology, 13, 241–262.

Vieira JN, Feijo AM, Bueno ME, Goncalves CL, Lund RG, Mendes JF, Villarreal JPV, Villela MM and Nascente PS, 2018. Evaluation of the frequency of Candida spp. in hospitalized and non-hospitalized subjects. Brazilian Journal of Biology = Revista brasileira de biologia, 78, 644–652.

Taverna CG, Cordoba S, Vivot M, Szusz W, Vivot W, Bosco-Borgeat ME and Davel G, 2018. Reidentification and antifungal susceptibility profile of Candida guilliermondii and Candida famata clinical isolates from a culture collection in Argentina. Medical Mycology.

Wayakanon K, Rueangyotchanthana K, Wayakanon P and Suwannachart C, 2018. The inhibition of Caco-2 proliferation by astaxanthin from Xanthophyllomyces dendrorhous. Journal of Medical Microbiology, 67, 507–513.

Wasilewska E and Wroblewsa B, 2018. Effectiveness and safety of probiotic preparations in clinical treatment of inflammatory bowel disease. Postepy Higieny I Medycyny Doswiadczalnej, 72, 159–174.

Yenisehirli G, Ozveren G, Yenisehirli A and Bulut Y, 2018. In vitro susceptibilities of non-albicans Candida Species to Echinocandins, Azoles, and Amphotericin B in Tokat, Turkey. Jundishapur Journal of Microbiology, 11, e59404.

Yang YC and Mao J, 2018. Value of platelet count in the early diagnosis of nosocomial invasive fungal infections in premature infants. Platelets, 29, 65–70.

**Viruses used for plant protection**

**Alphaflexiviridae**

None.

**Baculoviridae**

None.
### Table D.1: Articles that arrived to the article evaluation phase for the QPS status yeasts group

Thirty-five articles reached the article evaluation phase (final step of the ELS) for the QPS status yeasts group.\(^{(a),(b)}\)

| Not relevant for the QPS exercise | Articles not in English, no full text or not describing safety concerns | 14 ref. |
|-----------------------------------|---------------------------------------------------------------------|--------|
| Relevant to the QPS exercise      | Articles dealing with safety concerns                               | 21 ref.|
|                                   | Asi et al. (2018), Al-Tekreeti et al. (2018), Charsizadeh c) et al. (2018), Dangarembizi et al. (2018), Charsizadeh (b) et al. (2018), Charsizadeh (a) et al. (2018), Jahanshiriet al. (2018), Kumari et al. (2018), Ortiz et al. (2018), Mohamed et al. (2018), Nejat et al. (2018), Rajkowska et al. (2018), Scapaticci et al. (2018), Sav et al. (2018), Siavoshi et al. (2018), Sekyere et al. (2018), Vieira et al. (2018), Taverna et al. (2018), Wasilewska et al. (2018), Yenisehirli et al. (2018), Yang and Mao (2018)| Any methodological problem identified? | Yes | 6 ref. |
|                                   | Article(s) not considered because of:                                 | Methodology used for identity confirmation of the microorganism | 6 ref. |
|                                   | Reliability of the source attribution                                  | Rajkowska et al. (2018), Vieira et al. (2018), Yenisehirli et al. (2018)| 3 ref. |
|                                   | Misuse of the microorganism                                           | 0 ref. |
|                                   | Predisposing factors in the exposed subjects                          | Yang and Mao (2018) | 1 ref. |
|                                   | Other reasons                                                          | 0 ref. |
|                                   | No                                                                   | Articles describing any safety concern on: | Human health | 13 ref. |
|                                   | 15 ref.                                                               | No | 15 ref. |

\(^{(a)}\) Any methodological problem identified?  
\(^{(b)}\) Relevant to the QPS exercise  

- \(^{(a)}\) 6 ref.  
- \(^{(b)}\) 3 ref.  
- \(^{(c)}\) 3 ref.  
- 1 ref.  
- 0 ref.  

**BIOHAZ statement on QPS: suitability of taxonomic units notified until September 2018**

www.efsa.europa.eu/efsajournal
| Topic                  | References                                      |
|-----------------------|-------------------------------------------------|
| Animal health         | 1 ref. Dangarembizi et al. (2018)                |
| Environment           | 0 ref.                                          |
| AMR                   | 4 ref. Scapaticci et al. (2018), Sav et al. (2018), Sekyere et al. (2018), Taverna et al. (2018) |
| Other aspects         | 0 ref.                                          |

(a): Please refer to Appendix D for the complete list of references.
(b): Number of references (ref.) indicated for each step.
Appendix E – The 2016 updated list of QPS Status recommended biological agents in support of EFSA risk assessments

The list of QPS status recommended biological agents (EFSA BIOHAZ Panel, 2016) is being maintained in accordance with the self-task mandate of the BIOHAZ Panel (2017–2019). Possible additions to this list are included around every 6 months, with the first Panel Statement adopted in June 2017 and the last Panel Statement planned for adoption in December 2019. These additions are published as updates to the Scientific Opinion (EFSA BIOHAZ Panel, 2016); the latest update is available at https://doi.org/10.2903/j.efsa.2017.4664 and, as of January 2018, also as supporting information linked to every Panel Statement available on the Knowledge Junction at https://doi.org/10.5281/zenodo.1146566.
## Appendix F – Microbial species as notified to EFSA, received between April and September 2018 (reply to ToR 1)

| EFSA risk assessment area | Microorganism species/strain | Intended use | EFSA Question number(a) and EFSA webpage link(b) | Additional information provided by the EFSA Scientific Unit | Previous QPS status?(c) | To be evaluated? yes or no(d) |
|---------------------------|-------------------------------|--------------|-----------------------------------------------|----------------------------------------------------------|-------------------------|-----------------------------|
| **Bacteria**              |                               |              |                                               |                                                          |                         |                             |
| Feed additives            | *Bacillus amyloliquefaciens* DSM 25840 | Zootechnical additive | EFSA-Q-2018-00678 Gut flora stabilisers | Yes | No |
| Feed additives            | *Bacillus licheniformis* DSM 5749 and *Bacillus subtilis* DSM 5750 | Zootechnical additive | EFSA-Q-2018-00668 Gut flora stabilisers | Yes | No |
| Feed additives            | *Bacillus licheniformis* ENV01/DSM 32457 | Technological additive | EFSA-Q-2018-00690 Silage additives | Yes | No |
| Feed additives            | *Bacillus subtilis* C-3102, DSM 15544 | Zootechnical additive | EFSA-Q-2018-00677 Gut flora stabilisers | Yes | No |
| Feed additives            | *Bacillus subtilis* DSM 25841 | Zootechnical additive | EFSA-Q-2018-00679 Gut flora stabilisers | Yes | No |
| Feed additives            | *Bacillus subtilis* DSM 28343 | Zootechnical additive Production of γ-arginine | EFSA-Q-2018-00684 Gut flora stabilisers | Yes | No |
| Feed additives            | *Bacillus subtilis* DSM 28344 | Zootechnical additive Production of endo-1,4-beta-xylanase | EFSA-Q-2018-00669 Digestibility enhancers | Yes | No |
| Feed additives            | *Corynebacterium glutamicum* | Nutritional additive Production of lysine | EFSA-Q-2018-00427 Amino acids | Yes | No |
| Feed additives            | *Corynebacterium glutamicum* | Nutritional additive Production of 1-lysine monohydrochloride and concentrated liquid 1-lysine (base) | EFSA-Q-2018-00507 Amino acids | Yes | No |
| Food enzymes, food additives and flavourings | *Corynebacterium glutamicum* (strain FIS002) | Production of food enzyme D-psicose 3-epimerase | EFSA-Q-2018-00115 | Yes | No |
| Novel Food                | *Corynebacterium glutamicum* (strain FIS002) | Novel Food Production of allulose which involves the epimerisation of fructose at the C-3 position, in a reaction catalysed by γ-psicose 3-epimerase, which is contained within a non-viable, immobilised *Corynebacterium glutamicum* FIS002 | EFSA-Q-2018-00472 Summary of application: https://ec.europa.eu/food/sites/food/files/safety/docs/novel-food_ongoing-app_allulose.pdf | Yes | No |

---

**BioHAZ statement on QPS: suitability of taxonomic units notified until September 2018**

www.efsa.europa.eu/efsajournal
| EFSA risk assessment area | Microorganism species/strain | Intended use | EFSA Question number(a) and EFSA webpage link(b) | Additional information provided by the EFSA Scientific Unit | Previous QPS status?(c) | To be evaluated? yes or no(d) |
|--------------------------|------------------------------|--------------|-----------------------------------------------|-------------------------------------------------|------------------------|-----------------------------|
| Feed additives           | Corynebacterium glutamicum* KCCM 10227 | Nutritional additive Production by fermentation of L-lysine of monohydrochloride and concentrated liquid lysine | EFSA-Q-2018-00442 Amino acids | Yes | No |
| Feed additives           | Corynebacterium glutamicum* KCCM 80117 | Nutritional additive Production by fermentation of L-threonine | EFSA-Q-2018-00506 Amino acids | Yes | No |
| Feed additives           | Corynebacterium glutamicum* KCCM 80172 | Nutritional additive Production of histidine | EFSA-Q-2018-00438 Amino acids | Yes | No |
| Feed additives           | Corynebacterium glutamicum* KCCM 80176 | Nutritional additive Production of tryptophane | EFSA-Q-2018-00451 Amino acids | Yes | No |
| Feed additives           | Corynebacterium glutamicum* KCCM 80178 | Nutritional additive Production of L-threonine | EFSA-Q-2018-00627 Amino acids | Yes | No |
| Feed additives           | Corynebacterium glutamicum* KCCM 80179 | Nutritional additive/Sensory additive Production by fermentation of L-histidine monohydrochloride monohydrate | EFSA-Q-2018-00547 Amino acids/Flavouring compounds | Yes | No |
| Feed additives           | Corynebacterium glutamicum* KCCM 80182 | Nutritional additive/Sensory additive Production of L-arginine | EFSA-Q-2018-00612 Amino acids/Flavouring compounds | Yes | No |
| Feed additives           | Corynebacterium glutamicum* NITE BP-02524 | Nutritional additive/Sensory additive Production of L-glutamine | EFSA-Q-2018-00693 Amino acids/Flavouring compounds | Yes | No |
| Feed additives           | Enterococcus faecium DSM 7134 | Zootechnical additive | EFSA-Q-2018-00419 Gut flora stabilisers | No | No |
| Feed additives           | Enterococcus faecium DSM 7134 | Zootechnical additive | EFSA-Q-2018-00647 Gut flora stabilisers | No | No |
| Feed additives           | Escherichia coli CGMCC 11473 | Nutritional additive Production of L-threonine | EFSA-Q-2018-00695 Amino acids | No | No |
| Novel foods              | Escherichia coli commercial strain BL21 (DE3) Expression strain | Novel Food Production of a recombinant protein | EFSA-Q-2018-00316 Summary of this application: [https://ec.europa.eu/food/sites/food/files/safety/docs/novel-food_sum_ongoing-app_apoae_quorin.pdf](https://ec.europa.eu/food/sites/food/files/safety/docs/novel-food_sum_ongoing-app_apoae_quorin.pdf) | No | No |
| EFSA risk assessment area | Microorganism species/strain | Intended use | EFSA Question number(a) and EFSA webpage link(b) | Additional information provided by the EFSA Scientific Unit | Previous QPS status?(c) | To be evaluated? yes or no(d) |
|---------------------------|-----------------------------|-------------|-----------------------------------------------|--------------------------------------------------|----------------------|-----------------------------|
| Feed additives            | *Escherichia coli* K12 KCCM 80159 | Nutritional additive/Production by fermentation of L-valine | EFSA-Q-2018-00712 | Amino acids | No | No |
| Feed additives            | *Escherichia coli* KCCM 10534 | Nutritional additive/Production by fermentation of L-tryptophan | EFSA-Q-2018-00545 | Amino acids | No | No |
| Feed additives            | *Escherichia coli* KCCM 80180 and *Escherichia coli* KCCM 80181 | Sensory additive/Production by fermentation of L-cysteine monohydrochloride monohydrate | EFSA-Q-2018-00552 | Flavouring compounds | No | No |
| Feed additives            | *Escherichia coli* NITE BP-02351 | Nutritional additive/Sensory additive/Production of L-leucine | EFSA-Q-2018-00548 | Amino acids/Flavouring compounds | No | No |
| Feed additives            | *Escherichia coli* NITE SD 00268 | Nutritional additive/Production of L-histidine monohydrochloride monohydrate | EFSA-Q-2018-00546 | Amino acids | No | No |
| Novel foods               | *Komagataeibacter sucrofermentans* | Novel Food | EFSA-Q-2018-00294 | Summary of this application: [https://ec.europa.eu/food/sites/food/files/safety/docs/novel-food_sum_ongoing-app_bacterial-cellulose.pdf](https://ec.europa.eu/food/sites/food/files/safety/docs/novel-food_sum_ongoing-app_bacterial-cellulose.pdf) | No | Yes |
| Feed additives            | *Lactobacillus farciminis* CNCM 1-3699 | Zootecchnical additive | EFSA-Q-2018-00422 | Other zootecnical additives | Yes | No |
| Feed additives            | *Lactobacillus hilgardii* CNCM 1-4785 and *Lactobacillus buchneri* CNCM 1-4323 | Technological additive | EFSA-Q-2018-00287 | Silage additive | Yes | No |
| Feed additives            | *Lactobacillus rhamnosus* CNCM 1-3698 | Zootecchnical additive | EFSA-Q-2018-00422 | Other zootecnical additives | Yes | No |
| EFSA risk assessment area | Microorganism species/strain | Intended use | EFSA Question number(a) and EFSA webpage link(b) | Additional information provided by the EFSA Scientific Unit | Previous QPS status?(c) | To be evaluated? yes or no(d) |
|--------------------------|-----------------------------|-------------|-----------------------------------------------|----------------------------------------------------------|------------------------|-----------------------------|
| Novel foods              | *Mycobacterium setense* strain Manresensis | Novel Food  | EFSA-Q-2018-00278 | Summary of this application: [https://ec.europa.eu/food/sites/food/files/safety/docs/novel-food_sum_ongoing-app_heat-killed-mycobacterium.pdf](https://ec.europa.eu/food/sites/food/files/safety/docs/novel-food_sum_ongoing-app_heat-killed-mycobacterium.pdf) | No                     | Yes                         |
| Feed additives           | *Pediococcus acidilactici* CNCM MA 18/5M | Zootechnical additive | EFSA-Q-2018-00632 | Other zootechnical additives | Yes                    | No                          |
| Feed additives           | *Pediococcus acidilactici* CNCM MA 18/5M | Zootechnical additive | EFSA-Q-2018-00641 | Gut flora stabilisers | Yes                    | No                          |
| Feed additives           | *Pseudomonas fluorescens* BDS0104 | Zootechnical additive Production of 6-phytase | EFSA-Q-2018-00421 | Digestibility enhancers | No                     | Yes                         |
| Food enzymes, food additives and flavourings | *Streptomyces mobaraensis* (strain DSM40587) | Production of food enzyme transglutaminase | EFSA-Q-2017-00615 | | No | No |

### Filamentous fungi

| Feed additives | *Aspergillus niger* CBS DSM 25770 | Zootechnical additive Production of 6-phytase | EFSA-Q-2018-00623 | Digestibility enhancers GMM | No | No |
|----------------|----------------------------------|------------------------------------------------|-------------------|-----------------------------|------------------------|-----------------------------|
| Feed additives | *Aspergillus niger* (CBS 109.713 and DSM 18404) | Zootechnical additive Production of endo-1,4-beta-xylanase and endo-1,4-beta-glucanase | EFSA-Q-2018-00417 | Digestibility enhancers GMM | No | No |
| Food enzymes, food additives and flavourings | *Aspergillus niger* (NZYM-BF) | Production of food enzyme glucoamylase | EFSA-Q-2018-00265 | | No | No |
| Feed additives | *Aspergillus oryzae* DSM 10287 | Zootechnical additive Production of endo-1,4-beta-xylanase | EFSA-Q-2018-00622 | Digestibility enhancers GMM | No | No |
| Feed additives | *Trichoderma citrinoviride* IMI SD142 | Zootechnical additive Production of endo-1,4-beta-xylanase | EFSA-Q-2018-00420 | Digestibility enhancers | No | No |

### Yeasts

| Feed additives | *Komagataella pastoris* CGMCC 12056 | Zootechnical additive Production of 6-phytase | EFSA-Q-2018-00478 | Digestibility enhancers GMM | Yes | No |

---

*Note: EFSA QPS: suitability of taxonomic units notified until September 2018*
| EFSA risk assessment area | Microorganism species/strain | Intended use | EFSA Question number(a) and EFSA webpage link(b) | Additional information provided by the EFSA Scientific Unit | Previous QPS status?(c) | To be evaluated? yes or no(d) |
|---------------------------|-------------------------------|--------------|-----------------------------------------------|----------------------------------------------------------|------------------------|--------------------------|
| Feed additives            | *Saccharomyces cerevisiae* CNCM I-1077 | Zootchnical additive | EFSA-Q-2018-00630 Digestibility enhancers and Gut flora stabilisers | Yes | No |
| Feed additives            | *Saccharomyces cerevisiae* CNCM I-1079 | Zootchnical additive | EFSA-Q-2018-00473 Gut flora stabilisers | Yes | No |
| Feed additives            | *Saccharomyces cerevisiae* CNCM I-1079 | Zootchnical additive | EFSA-Q-2018-00631 Other zootchnical additives | Yes | No |
| Feed additives            | *Saccharomyces cerevisiae* MUCL 39885 | Zootchnical additive | EFSA-Q-2018-00474 Gut flora stabilisers | Yes | No |
| Feed additives            | *Schizosaccharomyces pombe* (ATCC SD 5233) | Zootchnical additive Production of 6-phytase | EFSA-Q-2018-00516 Digestibility enhancers GMM | Yes | No |

*: Qualification that QPS only applies when the species is used for amino acid production is extended to other production purposes uses in this Panel Statement.
(a): To find more details on specific applications please access the EFSA website - Register of Questions: [http://registerofquestions.efsa.europa.eu/roqFrontend/ListOfQuestionsNoLogin?0&panel=ALL](http://registerofquestions.efsa.europa.eu/roqFrontend/ListOfQuestionsNoLogin?0&panel=ALL)
(b): Where no link is given this means that the risk assessment has not yet been published.
(c): Included in the QPS list as adopted in December 2016 (EFSA BIOHAZ Panel, 2017a,b) and respective updates which include new additions (latest: EFSA BIOHAZ Panel, 2018a,b).
(d): In the current Panel Statement.